View Filing Data

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2012	Mar. 11, 2013	Jun. 30, 2012
Document and Entity Information [Abstract]
Entity Registrant Name	ORASURE TECHNOLOGIES INC
Entity Central Index Key	0001116463
Document Type	10-K
Document Period End Date	Dec. 31, 2012
Amendment Flag	false
Document Fiscal Year Focus	2012
Document Fiscal Period Focus	FY
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Public Float			$ 535,010,265
Entity Common Stock, Shares Outstanding		55,518,043

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2012	Dec. 31, 2011
CURRENT ASSETS:
Cash	$ 87,888	$ 23,878
Accounts receivable, net of allowance for doubtful accounts of $285 and $170	17,545	17,159
Inventories	12,758	9,621
Prepaid expenses	1,719	1,682
Other current assets	493	496
Total current assets	120,403	52,836
PROPERTY AND EQUIPMENT, net	18,546	19,855
INTANGIBLE ASSETS, net	27,207	30,383
GOODWILL	25,445	24,740
OTHER ASSETS	124	47
TOTAL ASSETS	191,725	127,861
CURRENT LIABILITIES:
Current portion of long-term debt		7,292
Accounts payable	3,380	4,142
Deferred revenue	5,580	1,318
Accrued expenses	7,960	9,224
Total current liabilities	16,920	21,976
OTHER LIABILITIES	89
DEFERRED INCOME TAXES	4,401	5,635
COMMITMENTS AND CONTINGENCIES (Note 12)
STOCKHOLDERS' EQUITY
Preferred stock, par value $.000001, 25,000 shares authorized, none issued
Common stock, par value $.000001, 120,000 shares authorized, 55,281 and 47,393 shares issued and outstanding
Additional paid-in capital	333,522	249,640
Accumulated other comprehensive loss	(666)	(1,964)
Accumulated deficit	(162,541)	(147,426)
Total stockholders' equity	170,315	100,250
Total liabilities and stockholders' equity	$ 191,725	$ 127,861

Consolidated Balance Sheets (Parenthetical) - USD ($) shares in Thousands, $ in Thousands	Dec. 31, 2012	Dec. 31, 2011
Consolidated Balance Sheets [Abstract]
Accounts receivable, net of allowance for doubtful accounts	$ 285	$ 170
Preferred stock, par value	$ 0.000001	$ 0.000001
Preferred stock, shares authorized	25,000	25,000
Preferred stock, shares issued
Common stock, par value	$ 0.000001	$ 0.000001
Common stock, shares authorized	120,000	120,000
Common stock, shares issued	55,281	47,393
Common stock, shares outstanding	55,281	47,393

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
NET REVENUES:
Product	$ 85,753	$ 80,683	$ 71,199
Licensing and product development	2,067	1,198	3,816
Total revenue	87,820	81,881	75,015
COST OF PRODUCTS SOLD	32,249	30,164	27,655
Gross profit	55,571	51,717	47,360
OPERATING EXPENSES:
Research and development	12,445	18,406	13,192
Sales and marketing	37,087	22,383	20,728
General and administrative	22,309	20,325	16,794
Total operating expenses	71,841	61,114	50,714
Operating loss	(16,270)	(9,397)	(3,354)
INTEREST EXPENSE	(172)	(316)	(316)
OTHER INCOME (EXPENSE)	(70)	3	173
Loss before income taxes	(16,512)	(9,710)	(3,497)
INCOME TAX BENEFIT	(1,397)	(869)
NET LOSS	$ (15,115)	$ (8,841)	$ (3,497)
LOSS PER SHARE:
BASIC	$ (0.29)	$ (0.19)	$ (0.08)
DILUTED	$ (0.29)	$ (0.19)	$ (0.08)
SHARES USED IN COMPUTING LOSS PER SHARE:
BASIC	51,457	46,908	46,187
DILUTED	51,457	46,908	46,187

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Consolidated Statements of comprehensive loss [Abstract]
NET LOSS	$ (15,115)	$ (8,841)	$ (3,497)
OTHER COMPEHENSIVE INCOME (LOSS)
Currency translation adjustments	1,298	(1,729)	(4)
Other comprehensive income (loss)	1,298	(1,729)	(4)
COMPREHENSIVE LOSS	$ (13,817)	$ (10,570)	$ (3,501)

- Definition

The change in equity [net assets] of a business enterprise during a period from transactions and other events and circumstances from non-owner sources which are attributable to the reporting entity. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners, but excludes any and all transactions which are directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=6518256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6519514

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 10, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph A7
-Appendix A

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 87-21
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 19
-Article 5

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28, 29, 30
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9

+ Details

- Definition

Net of tax amount of other comprehensive income (loss) attributable to the parent entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569616-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569643-111683

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 30
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph c(3)
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 29
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit
Beginning Balance at Dec. 31, 2009	$ 103,807		$ 239,126	$ (231)	$ (135,088)
Beginning Balance, Shares at Dec. 31, 2009		45,930
Common stock issued upon exercise of options	$ 8		8
Common stock issued upon exercise of options, Shares	3	3
Vesting of restricted stock
Vesting of restricted stock, Shares		429
Purchase and retirement of treasury shares	$ (709)		(709)
Purchase and retirement of treasury shares, Shares		(136)
Compensation cost for restricted stock	2,354		2,354
Compensation cost for stock option grants	884		884
Net loss	(3,497)				(3,497)
Currency translation adjustments	(4)			(4)
Ending Balance at Dec. 31, 2010	102,843		241,663	(235)	(138,585)
Ending Balance, Shares at Dec. 31, 2010		46,226
Common stock issued upon exercise of options	$ 4,783		4,783
Common stock issued upon exercise of options, Shares	880	880
Vesting of restricted stock
Vesting of restricted stock, Shares		421
Purchase and retirement of treasury shares	$ (909)		(909)
Purchase and retirement of treasury shares, Shares		(134)
Compensation cost for restricted stock	2,521		2,521
Compensation cost for stock option grants	1,582		1,582
Net loss	(8,841)				(8,841)
Currency translation adjustments	(1,729)			(1,729)
Ending Balance at Dec. 31, 2011	100,250		249,640	(1,964)	(147,426)
Ending Balance, Shares at Dec. 31, 2011		47,393
Common stock issued upon exercise of options	$ 10,040		10,040
Common stock issued upon exercise of options, Shares	1,476	1,476
Vesting of restricted stock
Vesting of restricted stock, Shares		454
Issuance of common stock for public equity offering	$ 70,246		70,246
Issuance of common stock for public equity offering, Shares		6,100
Purchase and retirement of treasury shares	(1,560)		(1,560)
Purchase and retirement of treasury shares, Shares		(142)
Compensation cost for restricted stock	2,894		2,894
Compensation cost for stock option grants	2,262		2,262
Net loss	(15,115)				(15,115)
Currency translation adjustments	1,298			1,298
Ending Balance at Dec. 31, 2012	$ 170,315		$ 333,522	$ (666)	$ (162,541)
Ending Balance, Shares at Dec. 31, 2012		55,281

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
OPERATING ACTIVITIES:
Net loss	$ (15,115)	$ (8,841)	$ (3,497)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Stock-based compensation	5,197	4,100	3,229
Depreciation and amortization	7,250	4,891	3,012
Deferred income taxes	(1,397)	(868)
Inventory purchase accounting step-up adjustment	16	852
Changes in assets and liabilities
Accounts receivable	(296)	(3,377)	1,219
Inventories	(3,139)	(1,757)	1,499
Prepaid expenses and other assets	(99)	491	1,413
Accounts payable	(791)	911	(472)
Deferred revenue	4,254	112	(722)
Accrued expenses and other liabilities	(1,253)	492	(1,794)
Net cash (used in) provided by operating activities	(5,373)	(2,994)	3,887
INVESTING ACTIVITIES:
Proceeds from maturities and redemptions of short-term investments		1,895	2,841
Acquisition of DNA Genotek Inc., net of cash acquired		(49,730)
Payments for patents and product rights			(4,500)
Purchases of property and equipment	(2,019)	(2,505)	(2,106)
Net cash used in investing activities	(2,019)	(50,340)	(3,765)
FINANCING ACTIVITIES:
Repayments of long-term debt	(7,292)	(500)	(510)
Proceeds from the issuance of common stock, net of expenses	70,246
Proceeds from exercise of stock options	10,040	4,783	8
Repurchase of common stock	(1,560)	(909)	(709)
Net cash provided by (used in) financing activities	71,434	3,374	(1,211)
EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH	(32)	(5)	(2)
NET INCREASE (DECREASE) IN CASH	64,010	(49,965)	(1,091)
CASH, BEGINNING OF PERIOD	23,878	73,843	74,934
CASH, END OF PERIOD	$ 87,888	$ 23,878	$ 73,843

The Company

12 Months Ended

Dec. 31, 2012

The Company [Abstract]

THE COMPANY

1.	THE COMPANY:

We manufacture and market oral fluid diagnostic products and specimen collection devices using our proprietary oral fluid technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types. Our diagnostic products include tests that are performed on a rapid basis at the point of care and tests that are processed in a laboratory. These products are sold in the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities. In September 2012 we began selling our rapid point-of-care HIV test in the domestic consumer retail market. We also manufacture and sell oral fluid collection devices used to collect, stabilize and store samples of genetic material for molecular testing in the academic research, clinical genetic testing, pharmacogenomics, personalized medicine, and animal genetics markets. Our OraGene^® DNA sample collection kit provides an all-in-one system for the collection, stabilization and transportation of DNA in saliva. We also manufacture and sell medical devices used for the removal of benign skin lesions by cryosurgery, or freezing. One of our cryosurgery products has been sold in the over-the-counter or consumer retail markets in North America, Europe, Central and South America and Australia.

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2122150

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=7880789&loc=SL6228881-111685

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 272
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 720
-SubTopic 15
-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7668296&loc=d3e288-107754

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 915
-SubTopic 235
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 94-6
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 2-6
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 46R
-Paragraph 4, 14, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS140-4/FIN46(R)-8
-Paragraph 8, C1, C7
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2012

Summary of Significant Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

2.	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:

Principles of Consolidation and Basis of Presentation

The consolidated financial statements include the accounts of OraSure and its wholly-owned subsidiary, DNA Genotek Inc. (“DNAG” and, collectively with OraSure, the “Company”). All intercompany transactions and balances have been eliminated.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Such estimates include the valuation of accounts receivable and inventories and assumptions utilized in impairment testing for intangible assets and goodwill, as well as calculations related to contingencies and accruals, among others. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis, using historical experience and other factors, which management believes to be reasonable under the circumstances, including the current economic environment. We adjust such estimates and assumptions when facts and circumstances dictate. Illiquid credit markets, volatile equity, foreign currency markets, reductions in government funding, and declines in consumer spending have combined to increase the uncertainty inherent in such estimates and assumptions. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment and other factors will be reflected in the financial statements in those future periods.

Supplemental Cash Flow Information

In 2012, 2011 and 2010, we paid interest of $199, $318, and $340, respectively. In 2010, we capitalized interest of $20. No interest was capitalized in 2012 or 2011.

In 2012, we paid foreign and state income taxes of $22. In 2011, we received a refund of $15 for federal and state income taxes, net of state taxes paid. In 2010, we received a federal income tax refund of $597 related to refundable alternative minimum taxes paid in previous years, and we paid state income taxes of $12.

In 2012 and 2011, we recorded through the consolidated statements of operations an increase in our allowance for doubtful accounts of $115 and $64, respectively. In 2010, we recorded through the consolidated statement of operations a decrease in our allowance for doubtful accounts of $115. We had write-offs of $36 against the allowance for doubtful accounts in 2010. We had no material write-offs against the allowance for doubtful accounts in 2012 or 2011.

Accounts Receivable

Accounts receivable have been reduced by an estimated allowance for amounts that may become uncollectible in the future. This estimated allowance is based primarily on management’s evaluation of specific balances as they become past due, the financial condition of our customers and our historical experience related to write-offs.

Inventories

Inventories are stated at the lower of cost or market determined on a first-in, first-out basis, and include the cost of raw materials, labor and overhead. The majority of our inventories are subject to expiration dating. We continually evaluate quantities on hand and the carrying value of our inventories to determine the need for reserves for excess and obsolete inventories, based primarily on the estimated forecast of product sales. When factors indicate that impairment has occurred, either a reserve is established against the inventories’ carrying value or the inventories are completely written off, as in the case of lapsing expiration dates. In addition to reserving for these items identified through specific identification procedures, we also reserve for unidentified scrap or spoilage under a fixed-formula methodology.

Property and Equipment

Property and equipment are stated at cost. Additions or improvements are capitalized, while repairs and maintenance are charged to expense. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. Buildings are depreciated over twenty to forty years, while computer equipment, machinery and equipment, and furniture and fixtures are depreciated over two to ten years. Building improvements are amortized over their estimated useful lives. When assets are sold or otherwise disposed of, the related property amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statement of operations.

Intangible Assets

Intangible assets consist of a customer list, patents and product rights, acquired technology, tradenames and non-compete agreements. Patents and product rights consist of costs associated with the acquisition of patents, licenses and product distribution rights. The customer list, acquired technology, tradenames and non-compete agreements were all part of our acquisition of DNAG in August 2011. Intangible assets are amortized using the straight-line method over their estimated useful lives of one to fifteen years.

Goodwill

Goodwill represents the excess of the purchase price we paid over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in our acquisition of DNAG in August 2011. Goodwill is not amortized but rather is tested annually for impairment or more frequently if we believe that indicators of impairment exist. Performance of goodwill impairment testing permits us to make a qualitative evaluation about the likelihood of goodwill impairment. If we conclude that it is more likely than not that the fair value of a reporting unit is greater than its carrying amount, then we would not be required to perform the two-step quantitative impairment test. Otherwise, performing the two-step impairment test is necessary. The first step of the two-step quantitative impairment test involves comparing the fair values of the applicable reporting units with their aggregate carrying values, including goodwill. If the carrying value of a reporting unit exceeds the reporting unit’s fair value, we perform the second step of the test to determine the amount of the impairment loss, if any. The second step involves measuring any impairment by comparing the implied fair values of the affected reporting unit’s goodwill and intangible assets with the respective carrying values.

We performed our annual impairment test for goodwill as of July 31, 2012 and determined there was no impairment. Our assessment determined that our DNAG reporting unit had a fair value in excess of its carrying value (including goodwill of $25,179), of approximately 13%. We believe we have made reasonable estimates and assumptions to calculate the fair value of our reporting unit. If actual future results are not consistent with management’s estimates and assumptions, we may have to take an impairment charge in the future related to our goodwill. Future impairment tests will be performed annually in the fiscal third quarter, or sooner if a triggering event occurs.

Impairment of Long-Lived Assets

If indicators of impairment exist, we assess the recoverability of the affected long-lived assets, which include property and equipment and intangible assets, by determining whether the carrying value of such assets can be recovered through the sum of the undiscounted future cash flows from the use and eventual disposition of the asset. If impairment is indicated, we measure the amount of such impairment by comparing the carrying value of the assets to the fair value of these assets, which is generally determined based on the present value of the expected future cash flows associated with the use of the assets.

Revenue Recognition

We recognize product revenues when there is persuasive evidence that an arrangement exists, the price is fixed or determinable, title has passed and collection is reasonably assured. Product revenues are recorded net of allowances for any discounts or rebates. We do not grant price protection or product return rights (other than for our OraQuick ^® In-Home HIV tests, which we began to sell in the third quarter of 2012) to our customers, except for warranty returns. Historically, returns arising from warranty issues have been infrequent and immaterial. Accordingly, we expense warranty returns as incurred.

Our revenue practices with respect to the OraQuick^® In-Home HIV test will initially be different than those customarily used in the consumer package goods industry. Under U.S. generally accepted accounting principles, product revenue can not be recognized unless the amount of future returns can be reasonably estimated. Because our OraQuick^® In-Home HIV test is a new product for which we do not have a historical record of returns, we do not believe we can reasonably determine a return rate at this time. As a result we do not recognize revenue when we ship to the retail trade. For these product shipments, we invoice the retailer or distributor, record deferred revenue at gross invoice sales price, and classify the cost basis of the product held by the retailer or distributor as a component of inventory. Initially, we will only recognize revenue upon the consummation of a sale to the retail customer either in a store or over the internet. We expect to apply a more traditional revenue recognition policy such that revenue is recognized following shipment to the retailers or distributors when we believe we have sufficient data to develop a reasonable estimate of the level of expected returns.

Our net revenues recorded on sales of the OraQuick ^® In-Home HIV test represent total gross revenue less customer allowances, including estimates for cooperative advertising discounts, rebates, and chargebacks. These allowances are recorded as a reduction of gross revenue when recognized in our statement of operations. These allowances are established by management as our best estimate based on available information and are adjusted to reflect known changes in the factors that impact those estimates.

Royalty income from the grant of license rights is recognized during the period in which the revenue is earned and the amount is determinable from the licensee.

We record shipping and handling charges billed to our customers as product revenue and the related expense as cost of products sold. Taxes assessed by governmental authorities, such as sales or value-added taxes, are excluded from product revenues.

Deferred Revenue

We record deferred revenue when funds are received prior to the recognition of the associated revenue and also when shipments of our OraQuick^® In-Home HIV test are made to the retailers or distributors who have product return rights. Deferred revenue at December 31, 2012 and 2011 included customer prepayments of $1,880 and $1,318, respectively. As of December 31, 2012, it also included $3,700 related to OraQuick^® In-Home HIV tests, representing the value of product held by those retailers or distributors having product return rights.

Customer and Vendor Concentrations

As of December 31, 2012, one of our customers, CVS Distribution, Inc. accounted for approximately 11% of our accounts receivable balance. We had no significant concentrations (greater than 10%) in accounts receivable as of December 31, 2011 or in revenues for the years ended December 31, 2012, 2011 or 2010.

We currently purchase certain products and critical components of our products from sole-supply vendors, and if these vendors are unable or unwilling to supply the required components and products, we could be subject to substantial delays in the delivery of our products to our customers and increased costs. Furthermore, our subsidiary, DNAG, uses two third-party suppliers to manufacture its products. Our inability to have a timely supply of any of these components and products could have a material adverse effect on our business, as well as our financial condition and results of operations.

Research and Development

Research and development expenses consist of costs incurred in performing research and development activities, including salaries and benefits, facilities expenses, overhead expenses, clinical trial and related clinical manufacturing expenses, contract services and other outside expenses. Research and development costs are charged to expense as incurred. Clinical trial expenses include expenses associated with contract research organizations, or CROs. The invoicing from CROs can precede the services provided or can lag the service period by several months. Invoices paid prior to services being provided are recorded as a prepaid expense and then expensed appropriately as services are provided. We accrue the cost of services rendered but unbilled by CROs based on purchase order estimates provided by the CROs. Differences between actual and estimated clinical trial expenses recorded are generally not material and are adjusted for in the period in which they become known.

Advertising Expenses

Advertising costs are charged to expense as incurred. During 2012, 2011, and 2010, we incurred $6,310, $130, and $223, respectively, in advertising expenses. 2012 expenses include advertising associated with our OraQuick^® In-Home HIV test which we began selling in the consumer retail market in the fourth quarter.

Stock-Based Compensation

We account for stock-based compensation to employees and directors using the fair value method. We recognize compensation expense for stock option and restricted stock awards issued to employees and directors on a straight-line basis over the requisite service period of the award. To satisfy the exercise of options or to issue restricted stock, we issue new shares rather than purchase shares on the open market.

Income Taxes

We follow the asset and liability method for accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax basis of assets and liabilities, and operating loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates for the respective taxing jurisdiction that are expected to apply to taxable income in the years in which those temporary differences and operating loss and credit carryforwards are expected to be recovered, settled or utilized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

We assess the realizability of our net deferred tax assets on a quarterly basis. If, after considering all relevant positive and negative evidence, it is more likely than not that some portion or all of the net deferred tax assets will not be realized we reduce our net deferred tax assets by a valuation allowance. The realization of the net deferred tax assets is dependent on several factors, including the generation of sufficient taxable income prior to the expiration of our net operating loss carryforwards.

Foreign Currency Translation

The assets and liabilities of our foreign operations are translated into U.S. dollars at current exchange rates as of the balance sheet date, and revenues and expenses are translated at average exchange rates for the period. Resulting translation adjustments are reflected in accumulated other comprehensive loss, which is a separate component of stockholders’ equity.

Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than functional currency are included in income in the period in which the change occurs.

Loss Per Share

Basic and diluted loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per share is generally computed assuming the exercise or vesting of all dilutive securities such as common stock options and unvested restricted stock. Common stock options and unvested restricted stock totaling 5,314, 6,296, and 6,296 shares were outstanding as of December 31, 2012, 2011 and 2010, respectively. As a result of our net losses for the years ended December 31, 2012, 2011 and 2010, these shares were excluded from the respective periods’ computations of diluted loss per share, as their inclusion would have been anti-dilutive.

Accumulated Other Comprehensive Loss

We classify items of other comprehensive loss by their nature and disclose the accumulated balance of other comprehensive loss separately from accumulated deficit and additional paid-in capital in the stockholders’ equity section of our balance sheet.

Our accumulated other comprehensive loss for 2012, 2011, and 2010 consisted of foreign currency translation adjustments.

We have defined the Canadian dollar as the functional currency of our Canadian subsidiary, DNAG, and as such, the results of its operations are translated into U.S. dollars, which is the reporting currency of the Company. The $1,298 and ($1,729) currency translation adjustments recorded in 2012 and 2011, respectively, are largely the result of the translation of our Canadian operation’s financial statements into U.S. dollars.

Fair Value of Financial Instruments

As of December 31, 2012 and 2011, the carrying values of cash, accounts receivable, accounts payable and accrued expenses approximate their respective fair values based on their short-term nature.

Fair value measurements of all financial assets and liabilities that are being measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories:


Level 1:		Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2:		Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and

Level 3:		Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

Effective January 3, 2012, we implemented a nonqualified Deferred Compensation Plan for highly compensated employees. The assets of the plan are held in the name of the Company at a third-party financial institution. Separate accounts are maintained for each participant to reflect the amounts deferred by the participant and all earnings and losses on those deferred amounts. The assets of the plan are held in mutual funds. The fair value of the plan assets as of December 31, 2012 was $89 and was calculated using the market price of the mutual funds as of that date. All investments in the plan are classified as trading securities and measured as Level 1 instruments.

Reclassification

Certain prior period amounts have been reclassified to conform to current year presentation.

Business Combination

12 Months Ended

Dec. 31, 2012

Business Combination [Abstract]

Business Combination

3.	Business Combination

On August 17, 2011 (the “Acquisition Date”), we acquired all of the outstanding capital stock of DNAG, pursuant to the terms of a Support Agreement dated July 25, 2011. The purchase price was $49,750 CDN ($50,467 in U.S. dollars at the Acquisition Date exchange rate) and was funded by OraSure with cash on hand. The purchase price consisted of $50,000 CDN ($50,710 million in U.S. dollars at the Acquisition Date exchange rate) less a $250 CDN ($254 U.S. dollars) working capital adjustment received in the fourth quarter of 2011. Of the original $50,000 CDN purchase price, $5,000 CDN (or $5,071 in U.S. dollars at the Acquisition Date exchange rate) was deposited in escrow pursuant to the related support agreement. The payment for the working capital adjustment was funded from the escrow account. Subject to certain adjustments and the processing of any indemnification claims, $1.9 million CDN was released from the escrow fund to the seller in February 2013 with the balance to be released in February 2014.

The acquisition of DNAG strengthens OraSure’s leadership in oral fluid diagnostics, by providing OraSure with a complementary portfolio of products that enable easy and reliable collection, stabilization, transportation and storage of high quality nucleic acid (DNA and RNA) samples. These samples can then be used for a wide range of research and diagnostic applications.

We have accounted for the acquisition of DNAG using the acquisition method of accounting. Under the acquisition method of accounting, the total purchase price is allocated to the tangible and identifiable intangible assets acquired and the liabilities assumed based upon their estimated fair values as of the Acquisition Date. The excess of the fair value of the consideration paid over the estimated fair value of the assets acquired and liabilities assumed was recorded as goodwill. For purposes of the purchase price allocation, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. The fair value guidance also requires that the fair value measurements reflect the assumptions market participants use in pricing an asset or liability based upon the best information available. Under the acquisition method of accounting, acquisition related transaction costs, such as success-based banking fees and professional fees, are not included as a component of consideration transferred, but rather are accounted for as expenses in the periods in which the costs are incurred.

During 2011, we incurred a total of $2,634 of acquisition related costs, including success-based investment banking fees and accounting, legal and other professional fees, related to the DNAG acquisition, all of which were expensed and included in general and administrative expenses in the consolidated statement of operations for the year ended December 31, 2011.

The following table summarizes the allocation of the fair values of the assets acquired and the liabilities assumed at the Acquisition Date:


Current assets	$	3,734
Property, plant and equipment		715
Other assets		760
Intangible assets		28,502
Goodwill		25,619

Total assets acquired		59,330

Current liabilities		(1,388	)
Deferred tax liability		(7,475	)

Total liabilities assumed		(8,863	)

Purchase price		50,467
Less cash acquired		(737	)

Net cash paid	$	49,730

Included in the current assets acquired in the DNAG acquisition was inventory having an estimated fair value of $1,413. This fair value includes an $892 “step-up” adjustment to capitalize the estimated manufacturing profit in acquired finished goods inventory as of the Acquisition Date, of which we expensed $16 and $852 to cost of products sold during the years ended December 31, 2012 and 2011, respectively.

The results of operations associated with DNAG have been consolidated with those of the Company since the Acquisition Date. Total revenues of $6,216 and a net loss of $693, including $852 of inventory step-up as noted above, attributable to DNAG were recognized in the consolidated statement of operations for the year ended December 31, 2011.

The following unaudited condensed consolidated pro forma information sets forth the revenues, net loss and net loss per share of the Company for the years ended December 31, 2011 and 2010, as if the acquisition had occurred on January 1, 2010. The unaudited pro forma information presented below is not necessarily indicative of the results that would have been attained had the transaction occurred at an earlier date, nor are these results necessarily indicative of future consolidated results of operations of the Company.


	Years Ended December 31,
	2011			2010
Total revenues	$	89,966		$	89,303
Net loss		(10,911	)		(4,842	)
Loss per share:
Basic and diluted	$	(0.23	)	$	(0.10	)

The supplemental pro forma results for the year ended December 31, 2011 exclude $2,634 of transaction costs incurred by OraSure that were recorded in operating expenses.

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1524-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e7000-128479

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4922-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4934-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4926-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6996-128479

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1383-128463

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 88-16
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph F4
-Subparagraph e
-Appendix F

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51, 52
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 67-73
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Inventories

12 Months Ended

Dec. 31, 2012

Inventories [Abstract]

INVENTORIES

4.	INVENTORIES:


	December 31,
	2012		2011
Raw materials	$	6,777	$	5,768
Work in process		393		497
Finished goods		5,588		3,356

	$	12,758	$	9,621

Property and Equipment

12 Months Ended

Dec. 31, 2012

Property and Equipment [Abstract]

PROPERTY AND EQUIPMENT

5.	PROPERTY AND EQUIPMENT:


	December 31,
	2012			2011
Land	$	1,118		$	1,118
Buildings and improvements		16,589			16,532
Machinery and equipment		18,423			17,428
Computer equipment and software		5,989			5,167
Furniture and fixtures		1,692			1,669
Construction in progress		581			438

		44,392			42,352
Less accumulated depreciation		(25,846	)		(22,497	)

	$	18,546		$	19,855

Depreciation expense was $3,347, $2,934, and $2,510 for 2012, 2011, and 2010, respectively.

- Definition

The entire disclosure for long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. This disclosure may include property plant and equipment accounting policies and methodology, a schedule of property, plant and equipment gross, additions, deletions, transfers and other changes, depreciation, depletion and amortization expense, net, accumulated depreciation, depletion and amortization expense and useful lives, income statement disclosures, assets held for sale and public utility disclosures.

+ References + Details

Goodwill and Other Intangible Assets

12 Months Ended

Dec. 31, 2012

Goodwill and Other Intangible Assets [Abstract]

GOODWILL AND OTHER INTANGIBLE ASSETS

6.	GOODWILL AND OTHER INTANGIBLE ASSETS:

The changes in goodwill are as follows:


	December 31,
	2012		2011
Balance as of January 1	$	24,740	$	—
Goodwill from DNAG acquisition		—		25,619
Increase (decrease) related to foreign currency translation		705		(879	)

Balance as of December 31	$	25,445	$	24,740

Intangible assets consist of the following:


	Amortization Period (Years)		December 31, 2012
	Amortization Period (Years)		Gross		Accumulated Amortization			Net
Customer list		10	$	12,619	$	(1,673	)	$	10,946
Patents and product rights		3-10		10,449		(6,926	)		3,523
Acquired technology		7		9,802		(1,829	)		7,973
Tradename		15		4,837		(443	)		4,394
Non-compete agreements		1-3		842		(471	)		371

			$	38,550	$	(11,342	)	$	27,207


	Amortization Period (Years)		December 31, 2011
	Amortization Period (Years)		Gross		Accumulated Amortization			Net
Customer list		10	$	12,270	$	(441	)	$	11,829
Patents and product rights		3-10		10,449		(6,386	)		4,063
Acquired technology		7		9,531		(482	)		9,049
Tradename		15		4,703		(117	)		4,586
Non-compete agreements		1-3		1,021		(165	)		856

			$	37,974	$	(7,591	)	$	30,383

Patents and products rights are made up of the following:


	December 31,
	2012			2011
HIV-related	$	1,900		$	1,900
HCV-related		4,500			4,500
Lateral flow-related		1,500			1,500
Cryosurgery-related		2,549			2,549

		10,449			10,449
Less accumulated amortization		(6,926	)		(6,386	)

	$	3,523		$	4,063

Amortization expense for 2012, 2011, and 2010 was $3,903, $1,957, and $502, respectively.

Amortization expense for each of the five succeeding fiscal years is estimated as follows:


2013	$	3,616
2014		3,483
2015		3,300
2016		3,300
2017		3,300
Beyond		10,208

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Accrued Expenses

12 Months Ended

Dec. 31, 2012

Accrued Expenses [Abstract]

ACCRUED EXPENSES

7.	ACCRUED EXPENSES:


	December 31,
	2012		2011
Payroll and related benefits	$	4,248	$	4,867
Royalties		1,948		1,986
Professional fees		413		835
Other		1,351		1,536

	$	7,960	$	9,224

Long-Term Debt

12 Months Ended

Dec. 31, 2012

Long-Term Debt [Abstract]

LONG-TERM DEBT

8.	LONG-TERM DEBT:

As of December 31, 2011, we had in place a $10,000,000 credit facility (the “Credit Facility”), as amended, with Comerica Bank (“Comerica”). Pursuant to the terms of the Credit Facility, principal and interest fixed at 4.15% per annum were payable monthly through August 27, 2012, at which time the remaining unpaid principal balance was payable. On July 30, 2012, we repaid the $7,042 principal balance outstanding under this Credit Facility and this Credit Facility has been terminated.

Income Taxes

12 Months Ended

Dec. 31, 2012

Income Taxes [Abstract]

INCOME TAXES

9.	INCOME TAXES:

Loss before income tax benefit consists of the following:


	2012			2011			2010
United States	$	(13,515	)	$	(8,147	)	$	(3,497	)
Canada		(2,997	)		(1,563	)		—

	$	(16,512	)	$	(9,710	)	$	(3,497	)

The components of the income tax provision (benefit) for the years ended December 31, 2012, 2011 and 2010 are as follows:


	2012			2011			2010
Deferred
Federal	$	(4,370	)	$	(2,674	)	$	(1,215	)
State		(272	)		(273	)		(92	)
Canada		(1,397	)		(869	)		—

		(6,039	)		(3,816	)		(1,307	)
Increase in valuation allowance		4,642			2,947			1,307

Total income tax benefit	$	(1,397	)	$	(869	)	$	—

For the years ended December 31, 2012 and 2011 we recorded an income tax benefit of $1,397 and $869, respectively, associated with DNAG’s loss before income taxes and certain Canadian research and development and investment tax credits. The income tax benefit associated with DNAG was considered realizable based upon the estimated scheduled reversal of the deferred tax liabilities recorded in connection with the acquisition of DNAG. The income tax benefit for the current year ended December 31, 2012 was negatively impacted by a $428 adjustment to DNAG’s deferred tax liability recorded in the second quarter of 2012 to reflect a change in the enacted Canadian provincial tax rates.

A reconciliation of the statutory United States federal income tax rate to our effective tax rate for each of the years ended December 31, 2012, 2011, and 2010 is as follows:


	2012			2011			2010
Statutory U.S. federal income tax rate		(34.0	)%		(34.0	)%		(34.0	)%
State income taxes, net of federal benefit		(1.2	)		(1.9	)		(0.9	)
Canadian income taxes		(8.5	)		(8.9	)		—
Nondeductible expenses and other		1.0			5.3			6.8
U.S. research and development credits		(0.3	)		(5.7	)		(9.7	)
Change in valuation allowance, federal and state		34.5			36.3			37.8

Effective tax rate		(8.5	)%		(8.9	)%		—	%

Deferred income taxes reflect the tax effects of temporary differences between the basis of assets and liabilities recognized for financial reporting purposes and tax purposes, and net operating loss and tax credit carryforwards. Significant components of our total deferred tax asset as of December 31, 2012 and 2011 are as follows:


	2012			2011
Deferred tax assets (liabilities):
Net operating loss carryforwards	$	21,207		$	16,286
Inventories		1,781			1,216
Capitalized research and development costs		6,148			6,489
Accruals and reserves currently not deductible		2,123			1,968
Patent costs		1,202			1,552
Acquired intangible assets		(6,278	)		(6,635	)
Depreciation and amortization		(744	)		(1,019	)
Stock-based compensation		4,176			4,157
Research and development tax credit carryforward		2,378			2,103

Net deferred tax asset		31,993			26,117
Valuation allowance		(36,394	)		(31,752	)

Net deferred tax liability	$	(4,401	)	$	(5,635	)

In assessing the realizability of our net deferred tax asset, we consider all relevant positive and negative evidence in determining whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The realization of the gross deferred tax assets is dependent on several factors, including the generation of sufficient taxable income prior to the expiration of the NOL carryforwards. In 2008 we recorded an income tax charge to establish a full valuation allowance against our total U.S. net deferred tax asset. During the subsequent years, we continued to reevaluate our valuation allowance position and believe that it is more likely than not that our U.S. deferred income tax asset will not be realized in the immediate future. As such, we maintained a full valuation allowance against our net deferred tax assets as of December 31, 2012 and 2011 associated with our U.S. operations.

Our Federal NOL carryforwards expire as follows:


Year of Expiration	NOLs
2018-2019	$	16,273
2020-2024		16,397
2025-2031		14,476
2032		13,407

	$	60,553

The Tax Reform Act of 1986 contains provisions that limit the annual amount of NOLs available to be used in any given year in the event of a significant change in ownership. On September 29, 2000, two separate companies, STC Technologies, Inc. and Epitope, Inc., merged to form our Company. A significant change in ownership, as defined by Section 382 of the Internal Revenue Code, occurred in connection with this merger. As such, the utilization of NOLs generated prior to September 29, 2000 is limited to approximately $13,700 per year. We do not believe that this limitation will have a material adverse impact on the utilization of our Federal NOL carryforwards in future years.

As of December 31, 2012, our gross unrecognized tax benefits totaled $1,922 and based upon the valuation allowance for the U.S. operations the recognition of any tax benefit would not impact our effective tax rate. We record interest and penalties related to unrecognized tax benefits as a component of income tax expense. Interest and penalties were immaterial in 2012, 2011 and 2010. As a result of our net operating loss carryforward position, we are subject to audit by the Internal Revenue Service since our inception, as well as by several state jurisdictions for the years ended December 31, 2001 through 2012.

A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:


	2012			2011			2010
Balance as of January 1	$	2,015		$	2,090		$	2,045
Additions based on tax positions related to the current period		—			53			52
Additions for tax positions of prior periods		67			19			—
Reductions for tax positions of prior periods		(160	)		(147	)		(7	)

Balance as of December 31	$	1,922		$	2,015		$	2,090

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

+ Details

Stockholders' Equity

12 Months Ended

Dec. 31, 2012

Stockholders' Equity [Abstract]

STOCKHOLDERS' EQUITY:

10.

STOCKHOLDERS’ EQUITY:

Stock-Based Awards

We grant stock-based awards under the OraSure Technologies, Inc. Stock Award Plan, as amended and restated (the “Stock Plan”). The Stock Plan permits stock-based awards to employees, outside directors and consultants or other third-party advisors. Awards which may be granted under the Stock Plan include qualified incentive stock options, nonqualified stock options, stock appreciation rights, restricted awards, performance awards and other stock-based awards. We recognize compensation expense for stock option awards issued to employees and directors on a straight-line basis over the requisite service period of the award. To satisfy the exercise of options or to issue restricted stock, we normally issue new shares rather than purchase shares on the open market.

Under the terms of the Stock Plan, nonqualified options may be granted to eligible employees, including our officers at a price not less than 75 percent of the fair market value of a share of common stock on the date of grant. The option term and vesting schedule of such awards may be either unlimited or have a specified period in which to vest and be exercised. To date, options generally have been granted with ten-year exercise periods and an exercise price not less than the fair market value on the date of grant. Options generally vest over four years, with one quarter of the options vesting one year after grant and the remainder vesting on a monthly basis over the next three years.

As of December 31, 2012, 3,105 shares were available for future grants under the Stock Plan.

The fair value of each stock option was estimated on the date of the grant using the Black-Scholes option-pricing model using the following weighted-average assumptions:


	Years Ended December 31,
Black-Scholes Option Valuation Assumptions	2012			2011			2010
Risk-free interest rate⁽¹⁾		0.99	%		1.36	%		1.89	%
Expected dividend yield		—			—			—
Expected stock price volatility⁽²⁾		52	%		54	%		54	%
Expected life of stock options (in years)⁽³⁾		6			4			4

⁽¹⁾	Based on the constant maturity interest rate of U.S. Treasury securities whose term is consistent with the expected life of our stock options.

⁽²⁾	Expected stock price volatility is based upon historical experience.

⁽³⁾	Expected life of stock options is based upon historical experience.

The weighted-average grant date fair value of stock options granted during the years ended December 31, 2012, 2011 and 2010 was $5.38, $2.82 and $2.24, respectively.

Amounts recognized in the financial statements related to stock options were as follows:


	Years Ended December 31,
	2012			2011			2010
Total compensation cost during the year	$	2,262		$	1,579		$	877
Amounts capitalized into inventory during the year		(90	)		(58	)		(40	)
Amounts recognized in cost of products sold for amounts previously capitalized		58			36			63

Amounts charged against income	$	2,230		$	1,557		$	900

The aggregate intrinsic value of options exercised during the years ended December 31, 2012, 2011 and 2010 (the amount by which the market price of the stock on the date of exercise exceeded the exercise price) was $6,961, $2,490, and $9, respectively.

The following table summarizes the stock option activity under the Stock Plan:


	Options			Weighted-Average Exercise Price Per Share		Weighted-Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Outstanding on January 1, 2010		5,432		$	7.09
Granted		709			5.15
Exercised		(3	)		2.81
Forfeited		(634	)		7.19

Outstanding on December 31, 2010		5,504			6.83
Granted		1,143			6.78
Exercised		(880	)		5.44
Expired		(163	)		10.74
Forfeited		(188	)		8.11

Outstanding on December 31, 2011		5,416			6.89
Granted		783			11.18
Exercised		(1,476	)		6.80
Expired		(12	)		6.07
Forfeited		(67	)		7.49

Outstanding on December 31, 2012		4,644		$	7.64		6.4	$	2,805

Vested or expected to vest as of
December 31, 2012		4,595		$	7.62		6.3	$	2,800

Exercisable on December 31, 2012		3,115		$	7.10		5.3	$	2,285

As of December 31, 2012, there was $5,125 of unrecognized compensation expense related to unvested option awards that is expected to be recognized over a weighted-average period of 2.5 years.

Net cash proceeds from the exercise of stock options were $10,040, $4,783 and $8 for the years ended December 31, 2012, 2011 and 2010, respectively. As a result of our net operating loss carryforward position, no actual income tax benefit was realized from stock option exercises for these periods.

The following table summarizes information about stock options outstanding as of December 31, 2012:


Options outstanding							Options exercisable
Range of exercise prices	Number Outstanding		Weighted- Average Remaining Contractual Term (in years)		Weighted- Average Exercise Price Per Share		Number Exercisable		Weighted- Average Exercise Price Per Share
$2.55–$5.19		467		11.1	$	3.70		434	$	3.69
$5.19–$5.60		646		5.5		5.32		499		5.35
$5.72–$6.37		128		7.9		5.96		63		5.98
$6.63		743		8.1		6.63		328		6.63
$6.67–$8.06		574		5.1		7.74		481		7.82
$8.18–$8.28		673		2.8		8.23		666		8.23
$8.33–$9.56		594		3.4		9.23		567		9.25
$9.78–$10.99		83		3.3		10.26		77		10.23
$11.30		730		9.1		11.30		—
$12.14		6		9.5		12.14		—

		4,644		6.4	$	7.64		3,115	$	7.10

The Stock Plan also permits us to grant restricted shares of our common stock to eligible employees, including officers, and our outside directors. Generally, these shares are nontransferable until vested and are subject to vesting requirements and/or forfeiture, as determined by the Compensation Committee of our Board of Directors. The market value of these shares at the date of grant is recognized on a straight-line basis over the period during which the restrictions lapse. Compensation cost of $2,894, $2,521 and $2,354 related to restricted shares was recognized during the years ended December 31, 2012, 2011 and 2010, respectively.

The following table summarizes restricted stock award activity under the Stock Plan:


	Shares			Weighted-Average Grant Date Fair Value
Issued and unvested, January 1, 2010		820		$	5.44
Granted		454			5.19
Vested		(429	)		5.51
Forfeited		(53	)		5.15

Issued and unvested, December 31, 2010		792			5.28
Granted		527			6.53
Vested		(422	)		5.47
Forfeited		(18	)		6.63

Issued and unvested, December 31, 2011		879			5.91
Granted		259			11.31
Vested		(454	)		5.56
Forfeited		(14	)		7.77

Issued and unvested, December 31, 2012		670		$	8.19

Issued and expected to vest, December 31, 2012		670		$	8.19

As of December 31, 2012, there was $2,989 of unrecognized compensation expense related to unvested restricted stock awards that is expected to be recognized over a weighted average period of 1.6 years.

In connection with the vesting of restricted shares during the years ended December 31, 2012, 2011 and 2010, we purchased and immediately retired 142, 134 and 136 shares with aggregate values of $1,560, $909 and $709, respectively, in satisfaction of minimum tax withholding obligations.

Share Repurchase Program

On August 5, 2008, our Board of Directors approved a share repurchase program pursuant to which we are permitted to acquire up to $25,000 of our outstanding common shares. No shares were purchased and retired in 2012, 2011 or 2010.

Public Equity Offering

On July 11, 2012, we completed a public equity offering of 6,100 common shares, at a price of $12.30 per share, raising $75,030 before expenses of the offering. In connection with the offering, we paid $4,502 in underwriting discounts and commissions and incurred $282 in additional offering expenses.

- Definition

The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Section B
-Paragraph 7, 11A
-Chapter 1
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 20: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 21: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 22: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 129
-Paragraph 2, 3, 4, 5, 6, 7, 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 23: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

Business Segment Information

12 Months Ended

Dec. 31, 2012

Business Segment Information [Abstract]

BUSINESS SEGMENT INFORMATION:

11.

BUSINESS SEGMENT INFORMATION:

We operate our business within two reportable segments: our “OSUR” business, which consists of the development, manufacture and sale of oral fluid diagnostic products and specimen collection devices and the manufacture and sale of medical devices used for the removal of benign skin lesions by cryosurgery; and our molecular collection systems or “DNAG” business, which consists of the manufacture, development and sale of oral fluid collection devices that are used to collect, stabilize and store samples of genetic material for molecular testing. OSUR revenues consist primarily of products sold in the United States and internationally to various clinical laboratories, hospital, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities. In the fourth quarter of 2012, OSUR began selling a product in the domestic OTC marketplace. OSUR also derives revenues from licensing and product development activities. DNAG revenues consist primarily of products sold into the academic research, clinical genetic testing, pharmacogenomics, personalized medicine, animal and livestock genetics markets.

We organized our operating segments according to the nature of the products included in those segments. The accounting policies of the segments are the same as those described in the summary of significant accounting policies (see Note 2). We evaluate performance of our operating segments based on revenue and operating loss. We do not allocate interest income, interest expense, other income, other expenses or income taxes to our operating segments. Reportable segments have no inter-segment revenues.

The following table summarizes segment information for the years ended December 31, 2012, 2011, and 2010. During the year ended December 31, 2010 we operated within only one reportable segment.


	Years Ended December 31,
	2012			2011			2010
Net revenues:
OSUR	$	73,562		$	75,665		$	75,015
DNAG		14,258			6,216			—

Total	$	87,820		$	81,881		$	75,015

Operating loss:
OSUR	$	(13,395	)	$	(7,855	)	$	(3,354	)
DNAG		(2,875	)		(1,542	)		—

Total	$	(16,270	)	$	(9,397	)	$	(3,354	)

Depreciation and amortization:
OSUR	$	3,530		$	3,550		$	3,012
DNAG		3,720			1,341			—

Total	$	7,250		$	4,891		$	3,012

Capital expenditures:
OSUR	$	1,794		$	2,345		$	2,106
DNAG		225			160			—

Total	$	2,019		$	2,505		$	2,106


	December 31,
	2012		2011
Total assets:
OSUR	$	137,544	$	71,326
DNAG		54,181		56,535

Total	$	191,725	$	127,861

Our products are sold principally in the United States, Canada and Europe.

The following table represents total net revenues by geographic area, based on the location of the customer:


	For the Years Ended December 31,
	2012		2011		2010
United States	$	67,460	$	67,644	$	63,520
Europe		10,131		7,506		6,493
Other regions		10,229		6,731		5,002

	$	87,820	$	81,881	$	75,015

The following table represents total long-lived assets by geographic area:


	December 31,
	2012		2011
United States	$	17,868	$	18,954
Canada		589		706
Other regions		89		195

	$	18,546	$	19,855

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 131
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Commitments and Contingencies

12 Months Ended

Dec. 31, 2012

Commitments and Contingencies [Abstract]

COMMITMENTS AND CONTINGENCIES:

12.

COMMITMENTS AND CONTINGENCIES:

Sublicense Agreement

In June 2004, we entered into a sublicense agreement with a third party, pursuant to which we have been granted a limited, worldwide, non-exclusive sublicense to certain HIV-2 patents held by such party. Under the terms of this sublicense agreement, we are obligated to pay royalties based on a percentage of our net sales of certain products, which incorporate the technology covered by the licensed patents. Future minimum payments under this agreement are as follows:


2013	$	500
2014		500
2015		500
2016		500
2017		500
Thereafter		292

	$	2,792

Royalties from our commercial sale of products covered by the sublicense can be credited against these minimum royalty obligations.

Leases

We lease office space for our Canadian subsidiary and warehouse facilities under operating lease agreements. Future payments required under these non-cancelable leases are as follows:


2013	$	480
2014		243
2015		9
2016		6

	$	738

Rent expense for 2012, 2011 and 2010 was $510, $307, and $163, respectively.

Purchase Commitments

As of December 31, 2012, we had outstanding non-cancelable purchase commitments in the amount of $2,511 related to inventory, capital expenditures, and other goods or services.

Employment Agreements

Under terms of employment agreements with certain executive officers, extending through 2014, we are required to pay each individual a base salary for continuing employment with us. The agreements require payments totaling $2,201 and $748 in 2013 and 2014, respectively.

Litigation

From time-to-time, we are involved in certain legal actions arising in the ordinary course of business. In management’s opinion, based upon the advice of counsel, the outcomes of such actions are not expected to have a material adverse effect on our future financial position or results of operations.

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 14
-Paragraph 3
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 9, 10, 11, 12
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Retirement Plans

12 Months Ended

Dec. 31, 2012

Retirement Plans [Abstract]

RETIREMENT PLANS:

13.

RETIREMENT PLANS:

Substantially all of our U.S. employees are eligible to participate in the OraSure Technologies, Inc. 401(k) Plan (the “401(k) Plan”). The 401(k) Plan permits voluntary employee contributions to be excluded from an employee’s current taxable income under provisions of Internal Revenue Code Section 401(k) and the regulations thereunder. The 401(k) Plan also provides for us to match employee contributions up to $4,000 per year. Contributions to the 401(k) Plan, net of forfeitures, were $592, $533, and $597 in 2012, 2011, and 2010, respectively.

In addition to our existing 401(k) plan, effective January 3, 2012, we implemented a nonqualified Deferred Compensation plan to permit eligible highly compensated employees of the Company to defer receipt and taxation of their compensation each year. We may make discretionary contributions to the accounts of the participating employees in any amount either in cash or stock. Participants in the plan may not purchase OraSure stock as an investment vehicle. As of December 31, 2012, the value of the assets associated with the plan was $89 and is included in other assets in our consolidated balance sheet. Our obligation related to the deferred compensation plan is included in other liabilities in our consolidated balance sheet. As of December 31, 2012, our total obligation under this plan was $89.

Effective January 2, 2012, all regular full-time employees of DNAG are eligible to participate in the DNA Genotek Registered Retirement Savings Plan (the “RRSP”). The RRSP permits voluntary employee contributions to be excluded from an employee’s current taxable income and receive tax preferred treatment with Revenue Canada. The RRSP also provides for DNAG to match employee contributions up to $2,000 per year. Contributions to the RRSP were $113 in 2012.

- Definition

The entire disclosure for pension and other postretirement benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-URI http://asc.fasb.org/topic&trid=2235017

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Implementation Guide (Q and A)
-Number FAS88
-Paragraph 63
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5
-Subparagraph b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 106
-Paragraph 518
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 03-2
-Paragraph 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 87
-Paragraph 264
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5
-Subparagraph q
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5
-Subparagraph h
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 8
-Subparagraph m
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5, 6, 7, 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 158
-Paragraph 7, 21, 22
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS106-2
-Paragraph 20, 21, 22
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 30
-Paragraph 26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Quarterly Data (Unaudited)

12 Months Ended

Dec. 31, 2012

Quarterly Data [Abstract]

QUARTERLY DATA (Unaudited):

14.

QUARTERLY DATA (Unaudited):

The following tables summarize the quarterly results of operations for each of the quarters in 2012 and 2011. These quarterly results are unaudited, but in the opinion of management, have been prepared on the same basis as our audited financial information and include all adjustments (consisting only of normal recurring adjustments) necessary for a fair presentation of the information set forth herein.


	2012 Results
	Three months ended
	March 31, 2012			June 30, 2012			September 30, 2012			December 31, 2012
Net revenues	$	20,944		$	22,616		$	22,115		$	22,145
Costs and expenses		24,596			26,156			25,043			28,295

Operating loss		(3,652	)		(3,540	)		(2,928	)		(6,150	)
Other income (expense), net		(120	)		(113	)		(35	)		26

Loss before income taxes		(3,772	)		(3,653	)		(2,963	)		(6,124	)
Income tax benefit		(521	)		(91	)		(527	)		(258	)

Net loss	$	(3,251	)	$	(3,562	)	$	(2,436	)	$	(5,866	)

Loss per share
Basic	$	(0.07	)	$	(0.07	)	$	(0.04	)	$	(0.11	)

Diluted	$	(0.07	)	$	(0.07	)	$	(0.04	)	$	(0.11	)


	2011 Results
	Three months ended
	March 31, 2011			June 30, 2011			September 30, 2011⁽¹⁾			December 31, 2011⁽¹⁾
Net revenues	$	17,414		$	19,064		$	21,714		$	23,689
Costs and expenses		19,967			21,423			25,919			23,970

Operating loss		(2,553	)		(2,359	)		(4,205	)		(281	)
Other expense, net		(45	)		(79	)		(29	)		(158	)

Loss before income taxes		(2,598	)		(2,438	)		(4,234	)		(439	)
Income tax benefit		—			—			(315	)		(554	)

Net income (loss)	$	(2,598	)	$	(2,438	)	$	(3,919	)	$	115

Income (loss per share)
Basic	$	(0.06	)	$	(0.05	)	$	(0.08	)	$	—

Diluted	$	(0.06	)	$	(0.05	)	$	(0.08	)	$	—

⁽¹⁾	Includes the results of operations of DNA Genotek Inc. from the acquisition date of August 17, 2011, as well as $2,534 and $100 of transaction costs associated with the acquisition recorded in the three months ended September 30, and December 31, 2011, respectively.

- Definition

The entire disclosure for the quarterly financial data in the annual financial statements. The disclosure may include a tabular presentation of financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income or loss before extraordinary items and earnings per share data. It also includes an indication if the information in the note is unaudited, comments on the aggregate effect of year-end adjustments, and an explanation of matters or transactions that affect comparability or are pertinent to an understanding of the information furnished.

+ References + Details

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2012

Summary of Significant Accounting Policies [Abstract]

Principles of Consolidation and Basis of Presentation

Principles of Consolidation and Basis of Presentation

Use of Estimates

Use of Estimates

Supplemental Cash Flow Information

Supplemental Cash Flow Information

In 2012, 2011 and 2010, we paid interest of $199, $318, and $340, respectively. In 2010, we capitalized interest of $20. No interest was capitalized in 2012 or 2011.

Accounts Receivable

Accounts Receivable

Inventories

Inventories

Property and Equipment

Property and Equipment

Intangible Assets

Intangible Assets

Goodwill

Goodwill

Impairment of Long-Lived Assets

Impairment of Long-Lived Assets

Revenue Recognition

Revenue Recognition

Royalty income from the grant of license rights is recognized during the period in which the revenue is earned and the amount is determinable from the licensee.

Deferred Revenue

Deferred Revenue

Customer and Vendor Concentrations

Customer and Vendor Concentrations

Research and Development

Research and Development

Advertising Expenses

Advertising Expenses

Stock-Based Compensation

Stock-Based Compensation

Income Taxes

Income Taxes

Foreign Currency Translation

Foreign Currency Translation

Loss Per Share

Loss Per Share

Accumulated Other Comprehensive Loss

Accumulated Other Comprehensive Loss

Our accumulated other comprehensive loss for 2012, 2011, and 2010 consisted of foreign currency translation adjustments.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

As of December 31, 2012 and 2011, the carrying values of cash, accounts receivable, accounts payable and accrued expenses approximate their respective fair values based on their short-term nature.


Level 1:		Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2:		Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and

Level 3:		Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

Reclassification

Reclassification

Certain prior period amounts have been reclassified to conform to current year presentation.

Business Combination (Tables)

12 Months Ended

Dec. 31, 2012

Business Combination [Abstract]

Allocation of the estimated fair values of the assets acquired and the liabilities assumed at the Acquisition Date


Current assets	$	3,734
Property, plant and equipment		715
Other assets		760
Intangible assets		28,502
Goodwill		25,619

Total assets acquired		59,330

Current liabilities		(1,388	)
Deferred tax liability		(7,475	)

Total liabilities assumed		(8,863	)

Purchase price		50,467
Less cash acquired		(737	)

Net cash paid	$	49,730

Condensed pro forma consolidated information sets forth the combined revenues, net loss and net loss per share of the Company


	Years Ended December 31,
	2011			2010
Total revenues	$	89,966		$	89,303
Net loss		(10,911	)		(4,842	)
Loss per share:
Basic and diluted	$	(0.23	)	$	(0.10	)

- Definition

Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.

+ References + Details

Inventories (Tables)

12 Months Ended

Dec. 31, 2012

Inventories [Abstract]

Inventories


	December 31,
	2012		2011
Raw materials	$	6,777	$	5,768
Work in process		393		497
Finished goods		5,588		3,356

	$	12,758	$	9,621

Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2012

Property and Equipment [Abstract]

Schedule of Property and equipment


	December 31,
	2012			2011
Land	$	1,118		$	1,118
Buildings and improvements		16,589			16,532
Machinery and equipment		18,423			17,428
Computer equipment and software		5,989			5,167
Furniture and fixtures		1,692			1,669
Construction in progress		581			438

		44,392			42,352
Less accumulated depreciation		(25,846	)		(22,497	)

	$	18,546		$	19,855

Goodwill and Other Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2012

Goodwill and Other Intangible Assets [Abstract]

Schedule of changes in goodwill


	December 31,
	2012		2011
Balance as of January 1	$	24,740	$	—
Goodwill from DNAG acquisition		—		25,619
Increase (decrease) related to foreign currency translation		705		(879	)

Balance as of December 31	$	25,445	$	24,740

Summary of Intangible assets


	Amortization Period (Years)		December 31, 2012
	Amortization Period (Years)		Gross		Accumulated Amortization			Net
Customer list		10	$	12,619	$	(1,673	)	$	10,946
Patents and product rights		3-10		10,449		(6,926	)		3,523
Acquired technology		7		9,802		(1,829	)		7,973
Tradename		15		4,837		(443	)		4,394
Non-compete agreements		1-3		842		(471	)		371

			$	38,550	$	(11,342	)	$	27,207


	Amortization Period (Years)		December 31, 2011
	Amortization Period (Years)		Gross		Accumulated Amortization			Net
Customer list		10	$	12,270	$	(441	)	$	11,829
Patents and product rights		3-10		10,449		(6,386	)		4,063
Acquired technology		7		9,531		(482	)		9,049
Tradename		15		4,703		(117	)		4,586
Non-compete agreements		1-3		1,021		(165	)		856

			$	37,974	$	(7,591	)	$	30,383

Summary of Patents and products rights


	December 31,
	2012			2011
HIV-related	$	1,900		$	1,900
HCV-related		4,500			4,500
Lateral flow-related		1,500			1,500
Cryosurgery-related		2,549			2,549

		10,449			10,449
Less accumulated amortization		(6,926	)		(6,386	)

	$	3,523		$	4,063

Future expected amortization expense


2013	$	3,616
2014		3,483
2015		3,300
2016		3,300
2017		3,300
Beyond		10,208

- Definition

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

+ References + Details

Accrued Expenses (Tables)

12 Months Ended

Dec. 31, 2012

Accrued Expenses [Abstract]

Schedule of accrued expenses


	December 31,
	2012		2011
Payroll and related benefits	$	4,248	$	4,867
Royalties		1,948		1,986
Professional fees		413		835
Other		1,351		1,536

	$	7,960	$	9,224

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2012

Income Taxes [Abstract]

Schedule of loss before income tax benefit


	2012			2011			2010
United States	$	(13,515	)	$	(8,147	)	$	(3,497	)
Canada		(2,997	)		(1,563	)		—

	$	(16,512	)	$	(9,710	)	$	(3,497	)

Components of the income tax provision


	2012			2011			2010
Deferred
Federal	$	(4,370	)	$	(2,674	)	$	(1,215	)
State		(272	)		(273	)		(92	)
Canada		(1,397	)		(869	)		—

		(6,039	)		(3,816	)		(1,307	)
Increase in valuation allowance		4,642			2,947			1,307

Total income tax benefit	$	(1,397	)	$	(869	)	$	—

Reconciliation of the statutory United States federal income tax rate to domestic effective tax rate


	2012			2011			2010
Statutory U.S. federal income tax rate		(34.0	)%		(34.0	)%		(34.0	)%
State income taxes, net of federal benefit		(1.2	)		(1.9	)		(0.9	)
Canadian income taxes		(8.5	)		(8.9	)		—
Nondeductible expenses and other		1.0			5.3			6.8
U.S. research and development credits		(0.3	)		(5.7	)		(9.7	)
Change in valuation allowance, federal and state		34.5			36.3			37.8

Effective tax rate		(8.5	)%		(8.9	)%		—	%

Components of total deferred tax asset


	2012			2011
Deferred tax assets (liabilities):
Net operating loss carryforwards	$	21,207		$	16,286
Inventories		1,781			1,216
Capitalized research and development costs		6,148			6,489
Accruals and reserves currently not deductible		2,123			1,968
Patent costs		1,202			1,552
Acquired intangible assets		(6,278	)		(6,635	)
Depreciation and amortization		(744	)		(1,019	)
Stock-based compensation		4,176			4,157
Research and development tax credit carryforward		2,378			2,103

Net deferred tax asset		31,993			26,117
Valuation allowance		(36,394	)		(31,752	)

Net deferred tax liability	$	(4,401	)	$	(5,635	)

Expiry details of Federal net operating losses carryforwards


Year of Expiration	NOLs
2018-2019	$	16,273
2020-2024		16,397
2025-2031		14,476
2032		13,407

	$	60,553

Reconciliation of the beginning and ending amount of unrecognized tax benefits


	2012			2011			2010
Balance as of January 1	$	2,015		$	2,090		$	2,045
Additions based on tax positions related to the current period		—			53			52
Additions for tax positions of prior periods		67			19			—
Reductions for tax positions of prior periods		(160	)		(147	)		(7	)

Balance as of December 31	$	1,922		$	2,015		$	2,090

Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2012

Stockholders' Equity [Abstract]

Weighted-average assumptions for fair value measurement


	Years Ended December 31,
Black-Scholes Option Valuation Assumptions	2012			2011			2010
Risk-free interest rate⁽¹⁾		0.99	%		1.36	%		1.89	%
Expected dividend yield		—			—			—
Expected stock price volatility⁽²⁾		52	%		54	%		54	%
Expected life of stock options (in years)⁽³⁾		6			4			4

⁽¹⁾	Based on the constant maturity interest rate of U.S. Treasury securities whose term is consistent with the expected life of our stock options.

⁽²⁾	Expected stock price volatility is based upon historical experience.

⁽³⁾	Expected life of stock options is based upon historical experience.

Schedule of stock options recognized in financial statements


	Years Ended December 31,
	2012			2011			2010
Total compensation cost during the year	$	2,262		$	1,579		$	877
Amounts capitalized into inventory during the year		(90	)		(58	)		(40	)
Amounts recognized in cost of products sold for amounts previously capitalized		58			36			63

Amounts charged against income	$	2,230		$	1,557		$	900

Summary of company's stock option activity


	Options			Weighted-Average Exercise Price Per Share		Weighted-Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Outstanding on January 1, 2010		5,432		$	7.09
Granted		709			5.15
Exercised		(3	)		2.81
Forfeited		(634	)		7.19

Outstanding on December 31, 2010		5,504			6.83
Granted		1,143			6.78
Exercised		(880	)		5.44
Expired		(163	)		10.74
Forfeited		(188	)		8.11

Outstanding on December 31, 2011		5,416			6.89
Granted		783			11.18
Exercised		(1,476	)		6.80
Expired		(12	)		6.07
Forfeited		(67	)		7.49

Outstanding on December 31, 2012		4,644		$	7.64		6.4	$	2,805

Vested or expected to vest as of
December 31, 2012		4,595		$	7.62		6.3	$	2,800

Exercisable on December 31, 2012		3,115		$	7.10		5.3	$	2,285

Schedule of currently outstanding and exercisable stock option


Options outstanding							Options exercisable
Range of exercise prices	Number Outstanding		Weighted- Average Remaining Contractual Term (in years)		Weighted- Average Exercise Price Per Share		Number Exercisable		Weighted- Average Exercise Price Per Share
$2.55–$5.19		467		11.1	$	3.70		434	$	3.69
$5.19–$5.60		646		5.5		5.32		499		5.35
$5.72–$6.37		128		7.9		5.96		63		5.98
$6.63		743		8.1		6.63		328		6.63
$6.67–$8.06		574		5.1		7.74		481		7.82
$8.18–$8.28		673		2.8		8.23		666		8.23
$8.33–$9.56		594		3.4		9.23		567		9.25
$9.78–$10.99		83		3.3		10.26		77		10.23
$11.30		730		9.1		11.30		—
$12.14		6		9.5		12.14		—

		4,644		6.4	$	7.64		3,115	$	7.10

Summary of restricted stock award activity under the Stock Plan


	Shares			Weighted-Average Grant Date Fair Value
Issued and unvested, January 1, 2010		820		$	5.44
Granted		454			5.19
Vested		(429	)		5.51
Forfeited		(53	)		5.15

Issued and unvested, December 31, 2010		792			5.28
Granted		527			6.53
Vested		(422	)		5.47
Forfeited		(18	)		6.63

Issued and unvested, December 31, 2011		879			5.91
Granted		259			11.31
Vested		(454	)		5.56
Forfeited		(14	)		7.77

Issued and unvested, December 31, 2012		670		$	8.19

Issued and expected to vest, December 31, 2012		670		$	8.19

Business Segment Information (Tables)

12 Months Ended

Dec. 31, 2012

Business Segment Information [Abstract]

Summary of segment information


	Years Ended December 31,
	2012			2011			2010
Net revenues:
OSUR	$	73,562		$	75,665		$	75,015
DNAG		14,258			6,216			—

Total	$	87,820		$	81,881		$	75,015

Operating loss:
OSUR	$	(13,395	)	$	(7,855	)	$	(3,354	)
DNAG		(2,875	)		(1,542	)		—

Total	$	(16,270	)	$	(9,397	)	$	(3,354	)

Depreciation and amortization:
OSUR	$	3,530		$	3,550		$	3,012
DNAG		3,720			1,341			—

Total	$	7,250		$	4,891		$	3,012

Capital expenditures:
OSUR	$	1,794		$	2,345		$	2,106
DNAG		225			160			—

Total	$	2,019		$	2,505		$	2,106


	December 31,
	2012		2011
Total assets:
OSUR	$	137,544	$	71,326
DNAG		54,181		56,535

Total	$	191,725	$	127,861

Presentation of total net revenues and long-lived assets by geographic area


	For the Years Ended December 31,
	2012		2011		2010
United States	$	67,460	$	67,644	$	63,520
Europe		10,131		7,506		6,493
Other regions		10,229		6,731		5,002

	$	87,820	$	81,881	$	75,015


	December 31,
	2012		2011
United States	$	17,868	$	18,954
Canada		589		706
Other regions		89		195

	$	18,546	$	19,855

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References + Details

Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2012

Commitments and Contingencies [Abstract]

Schedule for future minimum payments under sublicense agreement


2013	$	500
2014		500
2015		500
2016		500
2017		500
Thereafter		292

	$	2,792

Schedule for future minimum lease payments under operating lease agreements


2013	$	480
2014		243
2015		9
2016		6

	$	738

Quarterly Data (Unaudited) (Tables)

12 Months Ended

Dec. 31, 2012

Quarterly Data [Abstract]

Summary of quarterly results of operations


	2012 Results
	Three months ended
	March 31, 2012			June 30, 2012			September 30, 2012			December 31, 2012
Net revenues	$	20,944		$	22,616		$	22,115		$	22,145
Costs and expenses		24,596			26,156			25,043			28,295

Operating loss		(3,652	)		(3,540	)		(2,928	)		(6,150	)
Other income (expense), net		(120	)		(113	)		(35	)		26

Loss before income taxes		(3,772	)		(3,653	)		(2,963	)		(6,124	)
Income tax benefit		(521	)		(91	)		(527	)		(258	)

Net loss	$	(3,251	)	$	(3,562	)	$	(2,436	)	$	(5,866	)

Loss per share
Basic	$	(0.07	)	$	(0.07	)	$	(0.04	)	$	(0.11	)

Diluted	$	(0.07	)	$	(0.07	)	$	(0.04	)	$	(0.11	)


	2011 Results
	Three months ended
	March 31, 2011			June 30, 2011			September 30, 2011⁽¹⁾			December 31, 2011⁽¹⁾
Net revenues	$	17,414		$	19,064		$	21,714		$	23,689
Costs and expenses		19,967			21,423			25,919			23,970

Operating loss		(2,553	)		(2,359	)		(4,205	)		(281	)
Other expense, net		(45	)		(79	)		(29	)		(158	)

Loss before income taxes		(2,598	)		(2,438	)		(4,234	)		(439	)
Income tax benefit		—			—			(315	)		(554	)

Net income (loss)	$	(2,598	)	$	(2,438	)	$	(3,919	)	$	115

Income (loss per share)
Basic	$	(0.06	)	$	(0.05	)	$	(0.08	)	$	—

Diluted	$	(0.06	)	$	(0.05	)	$	(0.08	)	$	—

⁽¹⁾	Includes the results of operations of DNA Genotek Inc. from the acquisition date of August 17, 2011, as well as $2,534 and $100 of transaction costs associated with the acquisition recorded in the three months ended September 30, and December 31, 2011, respectively.

Summary of Significant Accounting Policies (Details) shares in Thousands, $ in Thousands	1 Months Ended	12 Months Ended
	Jul. 31, 2012 USD ($)	Dec. 31, 2012 USD ($) Suppliers Customer shares	Dec. 31, 2011 USD ($) shares	Dec. 31, 2010 USD ($) shares
Property, Plant and Equipment [Line Items]
Deferred revenue		$ 5,580	$ 1,318
Significant Accounting Policies (Textual) [Abstract]
Interest paid		199	318	$ 340
Interest capitalized		0	0	20
Federal and state income taxes, refunded			15	597
Foreign and state income taxes paid		22		12
Increase or decrease in allowance for doubtful accounts		115	64	115
Allowance for doubtful accounts write- off		$ 0	$ 0	$ 36
Percentage of excess of fair value on carrying value		13.00%
Common stock options and unvested restricted stock totaling \| shares		5,314	6,296	6,296
Significant concentrations in accounts receivable			$ 0
Number of customers with major contribution in accounts receivable		$ 0	0	$ 0
Rate account receivables		11.00%
Number of our customers CVS Distribution Inc. accounted for approximately 11% \| Customer		1
Advertising expenses		$ 6,310	130	223
Currency translation adjustments		1,298	(1,729)	$ (4)
Fair value of plan asset		$ 89
Concentration rate account receivables		10.00%
DNA Genotek [Member]
Property, Plant and Equipment [Line Items]
Impairment of good will	$ 0
Fair value of goodwill		$ 25,179
Number of third-party suppliers to manufacture DNAG's products \| Suppliers		2
OraQuick In-Home HIV Test [Member]
Property, Plant and Equipment [Line Items]
Retail value of estimated inventory		$ 3,700
Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful life of Intangible assets		15 years
Minimum [Member]
Property, Plant and Equipment [Line Items]
Useful life of Intangible assets		1 year
Building [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful life of building and other assets		40 years
Building [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Useful life of building and other assets		20 years
Other Intangible Assets [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful life of building and other assets		10 years
Other Intangible Assets [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Useful life of building and other assets		2 years
Up Front Payment Arrangement [Member]
Property, Plant and Equipment [Line Items]
Deferred revenue		$ 1,880	$ 1,318

Business Combination (Details) - DNA Genotek [Member] $ in Thousands, $ in Thousands	Dec. 31, 2012 USD ($)	Aug. 17, 2011 CAD ($)	Aug. 17, 2011 USD ($)
Allocation of the estimated fair values of the assets acquired and the liabilities assumed at the Acquisition Date
Current assets	$ 3,734
Property, plant and equipment	715
Other assets	760
Intangible assets	28,502
Goodwill	25,619
Total assets acquired	59,330
Current liabilities	(1,388)
Deferred tax liability	(7,475)
Total liabilities assumed	(8,863)
Purchase price	50,467	$ 49,750	$ 50,467
Less cash acquired	(737)
Net cash paid	$ 49,730

Business Combination (Details 1) - DNA Genotek [Member] - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010
Combined revenues, net loss and net loss per share of the Company
Total revenues	$ 89,966	$ 89,303
Net loss	$ (10,911)	$ (4,842)
Loss per share:
Basic and diluted	$ (0.23)	$ (0.10)

Business Combination (Details Textual) $ in Thousands, $ in Thousands	1 Months Ended		3 Months Ended									12 Months Ended
	Aug. 31, 2011 CAD ($)	Aug. 31, 2011 USD ($)	Dec. 31, 2012 USD ($)	Sep. 30, 2012 USD ($)	Jun. 30, 2012 USD ($)	Mar. 31, 2012 USD ($)	Dec. 31, 2011 CAD ($)	Dec. 31, 2011 USD ($)	Sep. 30, 2011 USD ($)	Jun. 30, 2011 USD ($)	Mar. 31, 2011 USD ($)	Dec. 31, 2012 CAD ($)	Dec. 31, 2012 USD ($)	Dec. 31, 2011 USD ($)	Dec. 31, 2010 USD ($)	Aug. 17, 2011 CAD ($)	Aug. 17, 2011 USD ($)
Business Combination (Textual) [Abstract]
Acquisition related costs									$ 2,534
Cost of products sold														$ 852
Net revenues			$ 22,145	$ 22,115	$ 22,616	$ 20,944		$ 23,689	21,714	$ 19,064	$ 17,414		$ 87,820	81,881	$ 75,015
Net loss			(5,866)	$ (2,436)	$ (3,562)	$ (3,251)		115	$ (3,919)	$ (2,438)	$ (2,598)		(15,115)	(8,841)	$ (3,497)
Business Combination (Additional Textual) [Abstract]
Amount to be released from escrow fund next year												$ 1,900
DNA Genotek [Member]
Business Combination (Textual) [Abstract]
Acquisition purchase price																$ 50,000,000	$ 50,710,000
Purchase price funded with cash on hand			50,467										50,467			$ 49,750	$ 50,467
Escrow deposit disbursements related to property acquisition	$ 5,000	$ 5,071
Working capital adjustment							$ 250	254
Acquisition related costs								$ 2,634						2,634
Acquisition inventory cost			1,413										1,413
Adjustments to capitalized fair value inventory Step -up			$ 892										892
Cost of products sold													$ 16
Net revenues														6,216
Net loss														$ 693

Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2012	Dec. 31, 2011
Inventories
Raw materials	$ 6,777	$ 5,768
Work in process	393	497
Finished goods	5,588	3,356
Inventories	$ 12,758	$ 9,621

Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2012	Dec. 31, 2011
Schedule of Property and equipment
Property plant and equipment Gross	$ 44,392	$ 42,352
Less accumulated depreciation	(25,846)	(22,497)
Property plant and equipment Net	18,546	19,855
Land [Member]
Schedule of Property and equipment
Property plant and equipment Gross	1,118	1,118
Building and Improvements [Member]
Schedule of Property and equipment
Property plant and equipment Gross	16,589	16,532
Machinery and Equipment [Member]
Schedule of Property and equipment
Property plant and equipment Gross	18,423	17,428
Computer Equipment and Software [Member]
Schedule of Property and equipment
Property plant and equipment Gross	5,989	5,167
Furniture and Fixtures [Member]
Schedule of Property and equipment
Property plant and equipment Gross	1,692	1,669
Construction in Progress [Member]
Schedule of Property and equipment
Property plant and equipment Gross	$ 581	$ 438

Property and Equipment (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Property and Equipment (Textual) [Abstract]
Depreciation expenses	$ 3,347	$ 2,934	$ 2,510

Goodwill and Other Intangible Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
Schedule of changes in goodwill
Beginning Balance	$ 24,740
Goodwill from DNAG acquisition		$ 25,619
Increase (decrease) related to foreign currency translation	705	(879)
Ending Balance	$ 25,445	$ 24,740

- Definition

Carrying amount as of the balance sheet date, which is the cumulative amount paid and (if applicable) the fair value of any noncontrolling interest in the acquiree, adjusted for any amortization recognized prior to the adoption of any changes in generally accepted accounting principles (as applicable) and for any impairment charges, in excess of the fair value of net assets acquired in one or more business combination transactions.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=14024403&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 45
-Subparagraph e
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 43
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 72
-Subparagraph d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 45
-Subparagraph e
-Clause 1
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 68
-Subparagraph l
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 34
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Goodwill And Other Intangible Assets (Details 1) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
Summary of Intangible assets
Gross	$ 38,550	$ 37,974
Accumulated Amortization	(11,342)	(7,591)
Net	$ 27,207	$ 30,383
Minimum [Member]
Summary of Intangible assets
Amortization Period (Years)	1 year
Maximum [Member]
Summary of Intangible assets
Amortization Period (Years)	15 years
Customer lists [Member]
Summary of Intangible assets
Amortization Period (Years)	10 years	10 years
Gross	$ 12,619	$ 12,270
Accumulated Amortization	(1,673)	(441)
Net	10,946	11,829
Patent and product rights [Member]
Summary of Intangible assets
Gross	10,449	10,449
Accumulated Amortization	(6,926)	(6,386)
Net	$ 3,523	$ 4,063
Patent and product rights [Member] \| Minimum [Member]
Summary of Intangible assets
Amortization Period (Years)	3 years	3 years
Patent and product rights [Member] \| Maximum [Member]
Summary of Intangible assets
Amortization Period (Years)	10 years	10 years
Acquired technology [Member]
Summary of Intangible assets
Amortization Period (Years)	7 years	7 years
Gross	$ 9,802	$ 9,531
Accumulated Amortization	(1,829)	(482)
Net	$ 7,973	$ 9,049
Trade name [Member]
Summary of Intangible assets
Amortization Period (Years)	15 years	15 years
Gross	$ 4,837	$ 4,703
Accumulated Amortization	(443)	(117)
Net	4,394	4,586
Non-compete agreements [Member]
Summary of Intangible assets
Gross	842	1,021
Accumulated Amortization	(471)	(165)
Net	$ 371	$ 856
Non-compete agreements [Member] \| Minimum [Member]
Summary of Intangible assets
Amortization Period (Years)	1 year	1 year
Non-compete agreements [Member] \| Maximum [Member]
Summary of Intangible assets
Amortization Period (Years)	3 years	3 years

Goodwill And Other Intangible Assets (Details 2) - USD ($) $ in Thousands	Dec. 31, 2012	Dec. 31, 2011
Summary of Patents and products rights
Patent and products gross amount	$ 10,449	$ 10,449
Less accumulated amortization	(6,926)	(6,386)
Patent and products right, Net	3,523	4,063
HIV-related [Member]
Summary of Patents and products rights
Patent and products gross amount	1,900	1,900
HCV-related [Member]
Summary of Patents and products rights
Patent and products gross amount	4,500	4,500
Lateral flow-related [Member]
Summary of Patents and products rights
Patent and products gross amount	1,500	1,500
Cryosurgery-related [Member]
Summary of Patents and products rights
Patent and products gross amount	$ 2,549	$ 2,549

Goodwill and Other Intangible Assets (Details 3) $ in Thousands	Dec. 31, 2012 USD ($)
Future expected amortization expense
2013	$ 3,616
2014	3,483
2015	3,300
2016	3,300
2017	3,300
Beyond	$ 10,208

Goodwill and Other Intangible Assets (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Goodwill and Other Intangible Assets (Textual) [Abstract]
Amortization expense	$ 3,903	$ 1,957	$ 502

Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2012	Dec. 31, 2011
Schedule of accrued expenses
Payroll and related benefits	$ 4,248	$ 4,867
Royalties	1,948	1,986
Professional fees	413	835
Other	1,351	1,536
Accrued Expenses, Total	$ 7,960	$ 9,224

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References + Details

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References + Details

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References + Details

Long-Term Debt (Details) - USD ($)	1 Months Ended	12 Months Ended
Long-Term Debt (Details) - USD ($)	Jul. 31, 2012	Dec. 31, 2012	Jul. 30, 2012	Dec. 31, 2011
Long-Term Debt (Textual) [Abstract]
Credit facility, with Comerica Bank				$ 10,000,000
Credit facility, interest rate fixed during period		4.15%
Credit facility, borrowing capacity			$ 0
Prepaid of outstanding under Credit Facility	$ 7,042,000

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
Income Taxes (Details) - USD ($) $ in Thousands	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2011	Sep. 30, 2011	Jun. 30, 2011	Mar. 31, 2011	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Schedule of loss before income tax benefit
United States									$ (13,515)	$ (8,147)	$ (3,497)
Canada									(2,997)	(1,563)
Loss before income taxes	$ (6,124)	$ (2,963)	$ (3,653)	$ (3,772)	$ (439)	$ (4,234)	$ (2,438)	$ (2,598)	$ (16,512)	$ (9,710)	$ (3,497)

Income Taxes (Details 1) - USD ($) $ in Thousands	12 Months Ended
Income Taxes (Details 1) - USD ($) $ in Thousands	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Deferred
Federal	$ (4,370)	$ (2,674)	$ (1,215)
State	(272)	(273)	(92)
Canada	(1,397)	(869)
Total	(6,039)	(3,816)	(1,307)
Increase in valuation allowance	4,642	2,947	$ 1,307
Total income tax benefit	$ (1,397)	$ (869)

- Definition

The component of total income tax expense for the period comprised of the increase (decrease) during the period in the entity's domestic deferred tax assets and liabilities attributable to continuing operations as determined by applying the provisions of the federally enacted tax law.

+ References

+ Details

- Definition

The component of total income tax expense for the period comprised of the increase (decrease) in the entity's net foreign deferred tax assets and liabilities attributable to continuing operations as determined by applying the provisions of applicable enacted tax laws of countries other than the country of domicile.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Deferred Tax Expense (or Benefit)
-URI http://asc.fasb.org/extlink&oid=6510177

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.7)
-URI http://asc.fasb.org/extlink&oid=6889476&loc=d3e330036-122817

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph h
-Article 4

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 45
-Subparagraph b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 6
-Section I
-Subsection 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 289
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

- Definition

The component of total income tax expense for the period comprised of the increase (decrease) in the entity's state and local deferred tax assets and liabilities attributable to continuing operations as determined by applying the provisions of the applicable enacted tax laws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Deferred Tax Expense (or Benefit)
-URI http://asc.fasb.org/extlink&oid=6510177

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.7)
-URI http://asc.fasb.org/extlink&oid=6889476&loc=d3e330036-122817

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 45
-Subparagraph b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 8, 16, 17, 289
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 6
-Section I
-Subsection 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph h
-Article 4

+ Details

- Definition

The sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to pretax Income or Loss from continuing operations; income tax expense or benefit may include interest and penalties on tax uncertainties based on the entity's accounting policy.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a),(b)
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=21917399&loc=d3e32247-109318

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32672-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 45, 46
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph h
-Article 4

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 48
-Paragraph 15, 16, 19
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Income Taxes (Details 2)	12 Months Ended
Income Taxes (Details 2)	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Reconciliation of the statutory United States federal income tax rate to domestic effective tax rate
Statutory U.S. federal income tax rate	(34.00%)	(34.00%)	(34.00%)
State income taxes, net of federal benefit	(1.20%)	(1.90%)	(0.90%)
Canadian income taxes	(8.50%)	(8.90%)
Nondeductible expenses and other	1.00%	5.30%	6.80%
U.S. research and development credits	(0.30%)	(5.70%)	(9.70%)
Change in valuation allowance, federal and state	34.50%	36.30%	37.80%
Effective tax rate	(8.50%)	(8.90%)

Income Taxes (Details 3) - USD ($) $ in Thousands	Dec. 31, 2012	Dec. 31, 2011
Deferred tax assets (liabilities):
Net operating loss carryforwards	$ 21,207	$ 16,286
Inventories	1,781	1,216
Capitalized research and development costs	6,148	6,489
Accruals and reserves currently not deductible	2,123	1,968
Patent costs	1,202	1,552
Acquired intangible assets	(6,278)	(6,635)
Depreciation and amortization	(744)	(1,019)
Stock-based compensation	4,176	4,157
Research and development tax credit carryforward	2,378	2,103
Net deferred tax asset	31,993	26,117
Valuation allowance	(36,394)	(31,752)
Net deferred tax liability	$ (4,401)	$ (5,635)

Income Taxes (Details 4) $ in Thousands	Dec. 31, 2012 USD ($)
Expiry details of Federal net operating losses carryforwards
Operating loss carryforwards	$ 60,553
2018-2019 [Member]
Expiry details of Federal net operating losses carryforwards
Operating loss carryforwards	16,273
2020-2024 [Member]
Expiry details of Federal net operating losses carryforwards
Operating loss carryforwards	16,397
2025-2031 [Member]
Expiry details of Federal net operating losses carryforwards
Operating loss carryforwards	14,476
2032 [Member]
Expiry details of Federal net operating losses carryforwards
Operating loss carryforwards	$ 13,407

Income Taxes (Details 5) - USD ($) $ in Thousands	12 Months Ended
Income Taxes (Details 5) - USD ($) $ in Thousands	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Reconciliation of the beginning and ending amount of unrecognized tax benefits
Balance as of January 1	$ 2,015	$ 2,090	$ 2,045
Additions based on tax positions related to the current period		53	52
Additions for tax positions of prior periods	67	19
Reductions for tax positions of prior periods	(160)	(147)	(7)
Balance as of December 31	$ 1,922	$ 2,015	$ 2,090

Income Taxes (Details Textual) $ in Thousands	3 Months Ended						12 Months Ended
Income Taxes (Details Textual) $ in Thousands	Dec. 31, 2012 USD ($)	Sep. 30, 2012 USD ($)	Jun. 30, 2012 USD ($)	Mar. 31, 2012 USD ($)	Dec. 31, 2011 USD ($)	Sep. 30, 2011 USD ($)	Dec. 31, 2012 USD ($) Companies	Dec. 31, 2011 USD ($)	Dec. 31, 2010 USD ($)	Dec. 31, 2009 USD ($)
Operating Loss Carryforwards [Line Items]
Income tax benefit	$ (258)	$ (527)	$ (91)	$ (521)	$ (554)	$ (315)	$ (1,397)	$ (869)
Income Taxes (Textual) [Abstract]
Adjustment to deferred tax liability			$ 428
Number of companies merged \| Companies							2
Utilization of NOLs generated prior limited to	13,700						$ 13,700
Gross unrecognized tax benefits	$ 1,922				$ 2,015		1,922	2,015	$ 2,090	$ 2,045
DNA Genotek [Member]
Operating Loss Carryforwards [Line Items]
Income tax benefit							$ 1,397	$ 869

Stockholders' Equity (Details)	12 Months Ended
Stockholders' Equity (Details)	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Weighted-average assumptions for fair value measurement
Risk-free interest rate(1)	0.99%	1.36%	1.89%
Expected dividend yield
Expected stock price volatility(2)	52.00%	54.00%	54.00%
Expected life of stock options (in years)(3)	6 years	4 years	4 years

Stockholders' Equity (Details 1) - USD ($) $ in Thousands	12 Months Ended
Stockholders' Equity (Details 1) - USD ($) $ in Thousands	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Schedule of stock options recognized in financial statements
Total compensation cost during the year	$ 2,262	$ 1,579	$ 877
Amounts capitalized into inventory during the year	(90)	(58)	(40)
Amounts recognized in cost of products sold for amounts previously capitalized	58	36	63
Amounts charged against income	$ 2,230	$ 1,557	$ 900

Stockholders' Equity (Details 2) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Summary of company's stock option activity
Options, Outstanding, Beginning Balance	5,416	5,504	5,432
Weighted-Average Exercise Price Per Share, Outstanding, Beginning Balance	$ 6.89	$ 6.83	$ 7.09
Options, Outstanding, Granted	783	1,143	709
Weighted-Average Exercise Price Per Share, Outstanding, Granted	$ 11.18	$ 6.78	$ 5.15
Options, Outstanding, Exercised	(1,476)	(880)	(3)
Weighted-Average Exercise Price Per Share, Outstanding, Exercised	$ 6.80	$ 5.44	$ 2.81
Options, Outstanding, Expired	(12)	(163)
Weighted-Average Exercise Price Per Share, Outstanding, Expired	$ 6.07	$ 10.74
Options, Outstanding, Forfeited	(67)	(188)	(634)
Weighted-Average Exercise Price Per Share, Outstanding, Forfeited	$ 7.49	$ 8.11	$ 7.19
Options, Outstanding, Ending Balance	4,644	5,416	5,504
Weighted-Average Exercise Price Per Share, Outstanding, Ending Balance	$ 7.64	$ 6.89	$ 6.83
Weighted-Average Remaining Contractual Term (in years), Outstanding	6 years 4 months 24 days
Aggregate Intrinsic Value, Outstanding	$ 2,805
Options, Vested or expected to vest	4,595
Weighted-Average Exercise Price Per Share, Vested or expected to vest	$ 7.62
Weighted-Average Remaining Contractual Term (in years), Vested or expected to vest	6 years 3 months 18 days
Aggregate Intrinsic Value, Vested or expected to vest	$ 2,800
Options, Exercisable	3,115
Weighted-Average Exercise Price Per Share, Exercisable	$ 7.10
Weighted-Average Remaining Contractual Term (in years), Exercisable	5 years 3 months 18 days
Aggregate Intrinsic Value, Exercisable	$ 2,285

Stockholders' Equity (Details 3) shares in Thousands	12 Months Ended
Stockholders' Equity (Details 3) shares in Thousands	Dec. 31, 2012 $ / shares shares
Schedule of currently outstanding and exercisable stock option
Number Outstanding, Options Outstanding \| shares	4,644
Weighted- Average Remaining Contractual Term (in years), Options outstanding	6 years 4 months 24 days
Weighted- average Exercise Price Per Share, Options outstanding	$ 7.64
Number Exercisable, Options exercisable \| shares	3,115
Weighted- average Exercise Price Per Share, Options exercisable	$ 7.10
Range One [Member]
Schedule of currently outstanding and exercisable stock option
Range of exercise prices, Lower Range Limit	2.55
Range of exercise prices, Upper Range Limit	$ 5.19
Number Outstanding, Options Outstanding \| shares	467
Weighted- Average Remaining Contractual Term (in years), Options outstanding	11 years 1 month 6 days
Weighted- average Exercise Price Per Share, Options outstanding	$ 3.70
Number Exercisable, Options exercisable \| shares	434
Weighted- average Exercise Price Per Share, Options exercisable	$ 3.69
Range Two [Member]
Schedule of currently outstanding and exercisable stock option
Range of exercise prices, Lower Range Limit	5.19
Range of exercise prices, Upper Range Limit	$ 5.60
Number Outstanding, Options Outstanding \| shares	646
Weighted- Average Remaining Contractual Term (in years), Options outstanding	5 years 6 months
Weighted- average Exercise Price Per Share, Options outstanding	$ 5.32
Number Exercisable, Options exercisable \| shares	499
Weighted- average Exercise Price Per Share, Options exercisable	$ 5.35
Range Three [Member]
Schedule of currently outstanding and exercisable stock option
Range of exercise prices, Lower Range Limit	5.72
Range of exercise prices, Upper Range Limit	$ 6.37
Number Outstanding, Options Outstanding \| shares	128
Weighted- Average Remaining Contractual Term (in years), Options outstanding	7 years 10 months 24 days
Weighted- average Exercise Price Per Share, Options outstanding	$ 5.96
Number Exercisable, Options exercisable \| shares	63
Weighted- average Exercise Price Per Share, Options exercisable	$ 5.98
Range Four [Member]
Schedule of currently outstanding and exercisable stock option
Range of exercise prices, Upper Range Limit	$ 6.63
Number Outstanding, Options Outstanding \| shares	743
Weighted- Average Remaining Contractual Term (in years), Options outstanding	8 years 1 month 6 days
Weighted- average Exercise Price Per Share, Options outstanding	$ 6.63
Number Exercisable, Options exercisable \| shares	328
Weighted- average Exercise Price Per Share, Options exercisable	$ 6.63
Range Five [Member]
Schedule of currently outstanding and exercisable stock option
Range of exercise prices, Lower Range Limit	6.67
Range of exercise prices, Upper Range Limit	$ 8.06
Number Outstanding, Options Outstanding \| shares	574
Weighted- Average Remaining Contractual Term (in years), Options outstanding	5 years 1 month 6 days
Weighted- average Exercise Price Per Share, Options outstanding	$ 7.74
Number Exercisable, Options exercisable \| shares	481
Weighted- average Exercise Price Per Share, Options exercisable	$ 7.82
Range Six [Member]
Schedule of currently outstanding and exercisable stock option
Range of exercise prices, Lower Range Limit	8.18
Range of exercise prices, Upper Range Limit	$ 8.28
Number Outstanding, Options Outstanding \| shares	673
Weighted- Average Remaining Contractual Term (in years), Options outstanding	2 years 9 months 18 days
Weighted- average Exercise Price Per Share, Options outstanding	$ 8.23
Number Exercisable, Options exercisable \| shares	666
Weighted- average Exercise Price Per Share, Options exercisable	$ 8.23
Range Seven [Member]
Schedule of currently outstanding and exercisable stock option
Range of exercise prices, Lower Range Limit	8.33
Range of exercise prices, Upper Range Limit	$ 9.56
Number Outstanding, Options Outstanding \| shares	594
Weighted- Average Remaining Contractual Term (in years), Options outstanding	3 years 4 months 24 days
Weighted- average Exercise Price Per Share, Options outstanding	$ 9.23
Number Exercisable, Options exercisable \| shares	567
Weighted- average Exercise Price Per Share, Options exercisable	$ 9.25
Range Eight [Member]
Schedule of currently outstanding and exercisable stock option
Range of exercise prices, Lower Range Limit	9.78
Range of exercise prices, Upper Range Limit	$ 10.99
Number Outstanding, Options Outstanding \| shares	83
Weighted- Average Remaining Contractual Term (in years), Options outstanding	3 years 3 months 18 days
Weighted- average Exercise Price Per Share, Options outstanding	$ 10.26
Number Exercisable, Options exercisable \| shares	77
Weighted- average Exercise Price Per Share, Options exercisable	$ 10.23
Range Nine [Member]
Schedule of currently outstanding and exercisable stock option
Range of exercise prices, Upper Range Limit	$ 11.30
Number Outstanding, Options Outstanding \| shares	730
Weighted- Average Remaining Contractual Term (in years), Options outstanding	9 years 1 month 6 days
Weighted- average Exercise Price Per Share, Options outstanding	$ 11.30
Range Ten [Member]
Schedule of currently outstanding and exercisable stock option
Range of exercise prices, Upper Range Limit	$ 12.14
Number Outstanding, Options Outstanding \| shares	6
Weighted- Average Remaining Contractual Term (in years), Options outstanding	9 years 6 months
Weighted- average Exercise Price Per Share, Options outstanding	$ 12.14

Stockholders' Equity (Details 4) - Restricted Stock [Member] - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Summary of restricted stock award activity under the Stock Plan
Shares, Issued and unvested, Beginning Balance	879	792	820
Weighted-Average Grant Date Fair Value, Issued and unvested, Beginning Balance	$ 5.91	$ 5.28	$ 5.44
Shares, Granted	259	527	454
Weighted-Average Grant Date Fair Value, Granted	$ 11.31	$ 6.53	$ 5.19
Shares, Vested	(454)	(422)	(429)
Weighted-Average Grant Date Fair Value, Vested	$ 5.56	$ 5.47	$ 5.51
Shares, Forfeited	(14)	(18)	(53)
Weighted-Average Grant Date Fair Value, Forfeited	$ 7.77	$ 6.63	$ 5.15
Shares, Issued and unvested, Ending Balance	670	879	792
Weighted-Average Grant Date Fair Value, Issued and unvested, Ending Balance	$ 8.19	$ 5.91	$ 5.28
Shares, Issued and expected to vest	670
Weighted-Average Grant Date Fair Value, Issued and expected to vest	$ 8.19

Stockholders' Equity (Details Textual) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	1 Months Ended		12 Months Ended
	Jul. 11, 2012	Aug. 31, 2008	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Net cash proceeds from the exercise of stock options			$ 10,040	$ 4,783	$ 8
Vesting of restricted shares, purchased			142	134	136
Total compensation cost			$ 5,197	$ 4,100	$ 3,229
Stockholders' Equity (Textual) [Abstract]
Percent of the fair market value of a share granted as Stock plan price			75.00%
Granted exercise periods			10 years
Option vesting period			4 years
Vesting of Options			Options generally vest over four years, with one quarter of the options vesting one year after grant and the remainder vesting on a monthly basis over the next three years.
Shares available for future grants under the Stock Plan			3,105
Income tax benefit realized from stock option exercises during period			$ 0	$ 0	$ 0
Amount share repurchase program of common shares		$ 25,000
Public equity offered, price per share	$ 12.30
Proceeds from public offering before expenses	$ 75,030		$ 70,246
Underwriting discounts and commissions	4,502
Additional offering expenses	$ 282
Common Stock
Stockholders' Equity (Textual) [Abstract]
Public equity offering, number of shares	6,100		6,100
Proceeds from public offering before expenses
Share Repurchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting of restricted shares, purchased			0	0	0
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted - average grant date fair value of stock options granted			$ 5.38	$ 2.82	$ 2.24
Aggregate intrinsic value of options exercised			$ 6,961	$ 2,490	$ 9
Expected weighted-average period for recognition of compensation expense related to unvested option awards			1 year 7 months 6 days
Net cash proceeds from the exercise of stock options			$ 10,040	4,783	8
Unrecognized compensation expense related to unvested option awards			2,989
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense related to unvested restricted stock awards			$ 5,125
Expected weighted-average period for recognition of compensation expense related to unvested option awards			2 years 6 months
Restricted shares of common stock, aggregate values			$ 1,560	909	709
Total compensation cost			$ 2,894	$ 2,521	$ 2,354

Business Segment Information (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2011	Sep. 30, 2011	Jun. 30, 2011	Mar. 31, 2011	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Summary of segment information
Net revenues	$ 22,145	$ 22,115	$ 22,616	$ 20,944	$ 23,689	$ 21,714	$ 19,064	$ 17,414	$ 87,820	$ 81,881	$ 75,015
Operating loss	(6,150)	$ (2,928)	$ (3,540)	$ (3,652)	(281)	$ (4,205)	$ (2,359)	$ (2,553)	(16,270)	(9,397)	(3,354)
Depreciation and amortization									7,250	4,891	3,012
Capital expenditures									2,019	2,505	2,106
Total assets	191,725				127,861				191,725	127,861
OSUR [Member]
Summary of segment information
Net revenues									73,562	75,665	75,015
Operating loss									(13,395)	(7,855)	(3,354)
Depreciation and amortization									3,530	3,550	3,012
Capital expenditures									1,794	2,345	$ 2,106
Total assets	137,544				71,326				137,544	71,326
DNAG [Member]
Summary of segment information
Net revenues									14,258	6,216
Operating loss									(2,875)	(1,542)
Depreciation and amortization									3,720	1,341
Capital expenditures									225	160
Total assets	$ 54,181				$ 56,535				$ 54,181	$ 56,535

Business Segment Information (Details 1) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2011	Sep. 30, 2011	Jun. 30, 2011	Mar. 31, 2011	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Presentation of Revenues and Long Lived Assets by Geographic Area [Abstract]
Revenues	$ 22,145	$ 22,115	$ 22,616	$ 20,944	$ 23,689	$ 21,714	$ 19,064	$ 17,414	$ 87,820	$ 81,881	$ 75,015
Long-lived Assets	18,546				19,855				18,546	19,855
United States [Member]
Presentation of Revenues and Long Lived Assets by Geographic Area [Abstract]
Revenues									67,460	67,644	63,520
Long-lived Assets	17,868				18,954				17,868	18,954
Canada [Member]
Presentation of Revenues and Long Lived Assets by Geographic Area [Abstract]
Long-lived Assets	589				706				589	706
Europe [Member]
Presentation of Revenues and Long Lived Assets by Geographic Area [Abstract]
Revenues									10,131	7,506	6,493
Other regions [Member]
Presentation of Revenues and Long Lived Assets by Geographic Area [Abstract]
Revenues									10,229	6,731	$ 5,002
Long-lived Assets	$ 89				$ 195				$ 89	$ 195

Business Segment Information (Details Textual) - Segment	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2010
Business Segment Information (Textual) [Abstract]
Number of reportable segment of company	2	1

Commitments and Contingencies (Details) $ in Thousands	Dec. 31, 2012 USD ($)
Schedule for future minimum payments under sublicense agreement
2013	$ 500
2014	500
2015	500
2016	500
2017	500
Thereafter	292
Total	$ 2,792

Commitments and Contingencies (Details 1) $ in Thousands	Dec. 31, 2012 USD ($)
Schedule for future minimum lease payments under operating lease agreements
2013	$ 480
2014	243
2015	9
2016	6
Total	$ 738

Commitments and Contingencies (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Commitments and Contingencies (Textual) [Abstract]
Rent expense	$ 510	$ 307	$ 163
Outstanding non-cancellable purchase commitments	2,511
Required Salary payment as per agreements with employees next year	2,201
Required Salary payment as per agreements with employees second fiscal year	$ 748

Retirement Plans (Details) - USD ($) $ in Thousands	12 Months Ended
Retirement Plans (Details) - USD ($) $ in Thousands	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Defined Contribution Plan Disclosure [Line Items]
Employee contributions	$ 4,000
Contributions to Plan, net of forfeitures	592	$ 533	$ 597
Retirement Plans (Textual) [Abstract]
Total obligation under plan	89
Value of the assets associated with the plan	89
RRSP [Member] \| DNA Genotek [Member]
Defined Contribution Plan Disclosure [Line Items]
Employee contributions	2,000
Contributions to Plan, net of forfeitures	$ 113

Quarterly Data (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2011	Sep. 30, 2011	Jun. 30, 2011	Mar. 31, 2011	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Summary of quarterly results of operations
Net revenues	$ 22,145	$ 22,115	$ 22,616	$ 20,944	$ 23,689	$ 21,714	$ 19,064	$ 17,414	$ 87,820	$ 81,881	$ 75,015
Costs and expenses	28,295	25,043	26,156	24,596	23,970	25,919	21,423	19,967
Operating loss	(6,150)	(2,928)	(3,540)	(3,652)	(281)	(4,205)	(2,359)	(2,553)	(16,270)	(9,397)	(3,354)
Other income (expense), net	26	(35)	(113)	(120)	(158)	(29)	(79)	(45)	(70)	3	173
Loss before income taxes	(6,124)	(2,963)	(3,653)	(3,772)	(439)	(4,234)	(2,438)	(2,598)	(16,512)	(9,710)	(3,497)
Income tax benefit	(258)	(527)	(91)	(521)	(554)	(315)			(1,397)	(869)
Net loss	$ (5,866)	$ (2,436)	$ (3,562)	$ (3,251)	$ 115	$ (3,919)	$ (2,438)	$ (2,598)	$ (15,115)	$ (8,841)	$ (3,497)
Income (loss per share)
Basic	$ (0.11)	$ (0.04)	$ (0.07)	$ (0.07)		$ (0.08)	$ (0.05)	$ (0.06)	$ (0.29)	$ (0.19)	$ (0.08)
Diluted	$ (0.11)	$ (0.04)	$ (0.07)	$ (0.07)		$ (0.08)	$ (0.05)	$ (0.06)	$ (0.29)	$ (0.19)	$ (0.08)

Quarterly Data (Unaudited) (Details Textual) - USD ($) $ in Thousands	Dec. 31, 2011	Sep. 30, 2011
Quarterly Data (Textual) [Abstract]
Transaction costs		$ 2,534
DNA Genotek [Member]
Quarterly Data (Textual) [Abstract]
Transaction costs	$ 2,634